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[h1]Abstract 1 
The International Liaison Committee on Resuscitation (ILCOR) has initiated a continuous 2 
review of new, peer-reviewed, published cardiopulmonary resuscitation (CPR) science. This is 3 
the third annual summary of the ILCOR International Consensus on CPR and Emergency 4 
Cardiovascular Care Science With Treatment Recommendations. It addresses the most recent 5 
published resuscitation evidence reviewed by ILCOR Task Force science experts. This summary 6 
addresses the role of cardiac arrest centers and dispatcher-assisted CPR, the role of 7 
extracorporeal CPR in adults and children, vasopressors in adults, advanced airway interventions 8 
in adults and children, targeted temperature management in children after cardiac arrest, initial 9 
oxygen concentration during resuscitation of newborns, and interventions for presyncope by first 10 
aid providers. Members from 6 ILCOR task forces have assessed, discussed, and debated the 11 
certainty of the evidence based on Grading of Recommendations, Assessment, Development, and 12 
Evaluation criteria, and their statements include consensus treatment recommendations. Insights 13 
into the deliberations of the task forces are provided in the “Justification and Evidence to 14 
Decision Framework Highlights” sections. The task forces also listed priority knowledge gaps 15 
for further research. 16 
  17 
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[h1]Introduction 1 
This is the third in a series of annual International Liaison Committee on Resuscitation (ILCOR) 2 
International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care 3 
Science With Treatment Recommendations (CoSTR) summary publications that summarizes the 4 
ILCOR Task Force analyses of published resuscitation evidence. The review this year addresses 5 
12 topics by 6 task forces. Draft CoSTRs were posted online between November 12, 2018, and 6 
March 20, 2019,1 and included the data reviewed and draft treatment recommendations, with 7 
comments accepted through April 4, 2019. The 12 draft CoSTR statements are now available 8 
online and have been viewed 23 654 times since the first posting.  9 
This summary statement contains the final wording of the CoSTR statements as approved by the 10 
ILCOR task forces and by the ILCOR member councils. This statement differs in several 11 
respects from the website draft CoSTRs: the language used to describe the evidence is not 12 
restricted to standard Grading of Recommendations, Assessment, Development, and Evaluation 13 
(GRADE) terminology, making it more transparent to a wider audience; the “Justification and 14 
Evidence to Decision Framework Highlights” sections have been expanded to provide more 15 
information about the rationale for treatment recommendations; finally, the task forces have 16 
prioritized knowledge gaps requiring future research studies.  17 
The CoSTRs are based on task force analysis of the data, using the GRADE approach to answer 18 
specific research questions. Each analysis has been detailed in a systematic review (SR), 19 
published by a Knowledge Synthesis Unit (KSU) or systematic reviewer and the ILCOR topic 20 
experts.2-11 The GRADE approach rates the certainty evidence for an  intervention and for each 21 
outcome as high, moderate, low, or very low. Data from randomized controlled trials (RCTs) is 22 
initially rated  as high-certainty evidence, and data from observational studies as low-certainty 23 
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evidence. Five factors may lead to downgrading of the certainty of evidence, and 3 factors may 1 
enable an upgrade of the certainty of the evidence (Tables 1 and 2).  2 
For each topic, the consensus on science (CoS) generally includes the pertinent outcome data 3 
listing (1) relative risk (RR) with 95% confidence interval (CI), and (2) risk difference (RD) with 4 
95% CI or absolute risk difference (ARD) with 95% CI and (3) patients with outcome/1000 5 
patients with 95% CI.  For clarity, much of this data has been presented in tables. The consensus 6 
on science is followed by the treatment recommendation (TR), the task force justification for the 7 
TR, and the important knowledge gaps identified by the task force.  8 
Readers are encouraged to monitor the ILCOR CoSTR website12 to provide feedback about 9 
planned SRs and to provide comments when additional draft reviews are posted. 10 
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Table 1. GRADE Terminology for Strength of Recommendation and Criteria for Evidence Certainty Assessment 1 
Strength of Recommendation 
Strong recommendation = We recommend Weak recommendation = We suggest 
Assessment Criteria for Certainty of Effect 
Study Design 
Certainty of Effect 
Begins at This Level 
Lower if Higher if 
Randomized trial High or moderate Risk of bias 
Inconsistency 
Indirectness 
Imprecision 
Publication bias 
Large effect 
Dose response 
All plausible confounding would reduce demonstrated effect or 
would suggest a spurious effect when results show no effect 
Observational trial Low or very low 
2 
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Table 2. GRADE Terminology 1 
Risk of bias  Study limitations in randomized trials include lack of allocation concealment, lack 
of blinding, incomplete accounting of patients and outcome events, selective 
outcome reporting bias, and stopping early for benefit. Study limitations in 
observational studies include failure to apply appropriate eligibility criteria, flawed 
measurement of exposure and outcome, failure to adequately control confounding, 
and incomplete follow-up. 
Inconsistency  Criteria for inconsistency in results include the following: Point estimates vary 
widely across studies; CIs show minimal or no overlap; statistical test for 
heterogeneity shows a low P value; and the I2 is large (a measure of variation in 
point estimates resulting from among-study differences).  
Indirectness  Sources of indirectness include data from studies with differences in population 
(eg, OHCA instead of IHCA, adults instead of children), differences in the 
intervention (eg, different CV ratios), differences in outcome, and indirect 
comparisons.  
Imprecision  Low event rates or small sample sizes will generally result in wide CIs and 
therefore imprecision. 
Publication bias  Several sources of publication bias include tendency not to publish negative studies 
and the influence of industry-sponsored studies. An asymmetrical funnel plot 
increases suspicion of publication bias. 
Good practice 
statements 
Guideline panels often consider it necessary to issue guidance on specific topics 
that do not lend themselves to a formal review of research evidence. The reason 
might be that research into the topic is unlikely to be located or would be 
considered unethical or infeasible. Criteria for issuing a nongraded good practice 
statement include the following: There is overwhelming certainty that the benefits 
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of the recommended guidance will outweigh harms, and a specific rationale is 
provided; the statements should be clear and actionable to a specific target 
population; the guidance is deemed necessary and might be overlooked by some 
providers if not specifically communicated; and the recommendations should be 
readily implementable by the specific target audience to which the guidance is 
directed. 
CI, confidence interval; CV indicates compression-ventilation; GRADE, Grading of 1 
Recommendations, Assessment, Development, and Evaluation; IHCA, in-hospital cardiac arrest; 2 
and OHCA, out-of-hospital cardiac arrest.  3 
 4 
The following topics are addressed in this CoSTR summary: 5 
 Basic Life Support 6 
– Dispatch Instruction in Adult Cardiopulmonary Resuscitation (CPR) 7 
 Advanced Life Support 8 
– Advanced Airway Interventions During Adult Cardiac Arrest 9 
– Use of Vasopressors in Cardiac Arrest 10 
– Extracorporeal Cardiopulmonary Resuscitation (ECPR) for Cardiac Arrest: Adults 11 
 Pediatric Life Support 12 
– Dispatcher Instruction in CPR: Dispatcher-Assisted CPR (DA-CPR)—Pediatrics 13 
– Advanced Airway Interventions in Pediatric Cardiac Arrest 14 
– ECPR: Infants and Children 15 
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– Targeted Temperature Management (TTM) After Cardiac Arrest 1 
 Neonatal Life Support 2 
– Initial Oxygen Concentration for Term Infants at Birth 3 
– Initial Oxygen Concentration for Preterm Infants at Birth  4 
 Education, Implementation, and Teams (EIT) and Advanced Life Support (ALS)   5 
– Cardiac Arrest Centers (CACs) Versus Non-CACs  6 
 First Aid 7 
– Presyncope 8 
Readers are encouraged to monitor the ILCOR website12 to provide feedback about planned SRs 9 
and to provide comments when additional draft reviews are posted. 10 
[h1]Basic Life Support 11 
[h2]Dispatch Instruction in Adult CPR 12 
The emergency medical dispatcher is an essential link in the chain of survival.13,14 In addition to 13 
dispatching emergency medical services (EMS) resources to medical emergencies, emergency 14 
medical dispatchers are increasingly being trained to recognize cardiac arrest, assist bystanders 15 
in initiating resuscitation, and support bystanders in optimizing resuscitation efforts. The 16 
international community is continuing to explore ways to increase bystander CPR for cardiac 17 
arrests. One such strategy involves dispatchers providing CPR instruction to callers/bystanders—18 
DA-CPR. For such a strategy to be successful, it requires (1) the EMS system to be configured to 19 
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support the dispatcher to offer DA-CPR and (2) the bystander to deliver CPR with support from 1 
the dispatcher. 2 
ILCOR commissioned an SR to address the effect of DA-CPR on outcomes for patients in out-3 
of-hospital cardiac arrest (OHCA).2 A draft CoSTR was posted for public comment on the 4 
ILCOR website15; the draft was viewed 1516 times during the public comment period. The Task 5 
Force reviewed the one comment that was posted during this public commenting period. 6 
[h3]Population, Intervention, Comparator, Outcome, Study Design, and Time Frame 7 
Population: Adults with presumed cardiac arrest in out-of-hospital settings 8 
Intervention: Patients/cases or EMS systems where DA-CPR is offered 9 
Comparators: Studies with comparators where either systems or specific cardiac arrest cases not 10 
offered DA-CPR are included 11 
Outcomes: Critical—survival with favorable neurologic function (at hospital discharge, 1 month, 12 
or 6 months), survival (to hospital discharge, 1 month, or 1 year), short-term survival (return of 13 
spontaneous circulation [ROSC], hospital admission), provision of bystander CPR; Important—14 
initial shockable rhythm, time to CPR 15 
Study Designs: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled 16 
before-and-after studies, cohort studies) eligible for inclusion 17 
Time Frame: All years and all languages included with the last search performed July 1, 2018; 18 
ongoing or unpublished studies identified through a search of ClinicalTrials.gov online registry16  19 
PROSPERO registration: CRD42018091427 20 
Soar 9 
© 2019 American Heart Association, Inc. 
Note: The pediatric information is summarized elsewhere in this document (see Pediatric Life 1 
Support, Dispatcher Instruction in CPR: DA-CPR—Pediatrics). 2 
[h3]Consensus on Science 3 
Over 5000 citations were reviewed, and 33 were identified as eligible for inclusion. These 4 
studies were classified into 2 categories: (1) systems: the comparison of outcomes when DA-5 
CPR was offered versus not offered, and (2) bystander delivery: the comparison of outcomes for 6 
patients receiving DA-CPR versus those receiving no bystander CPR or unassisted bystander 7 
CPR. No randomized clinical trials were identified. Given that the only available data consisted 8 
of observational studies, we separately listed data when it came from an analysis adjusted for 9 
known confounders because we felt this provided a better estimate of effect. The reliance on 10 
nonrandomized trials in the evidence review also means the reported findings are best regarded 11 
as associated with the CPR provided, or not, rather than necessarily caused by the interventions. 12 
[h4]Systems: Studies Comparing Outcomes for Patients When DA-CPR Instruction Was 13 
Offered With Outcomes for Patients When DA-CPR Was Not Offered 14 
For the comparison of outcomes in systems with DA-CPR programs, we identified 16 studies. 15 
These included 5 before-and-after studies,17-21 and 11 cohort studies22-32 Only 4 of these studies 16 
adjusted in some way for confounding variables.21,26,28,32 Table 3 provides a summary of the 17 
unadjusted and adjusted meta-analysis. 18 
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Table 3. Systems: Studies Comparing Outcomes for Adults When Dispatch-Assisted CPR Instruction Was Offered With 1 
Outcomes for Adults When Dispatch-Assisted CPR Was Not Offered 2 
 Unadjusted Analysis Adjusted Analysis 
Outcome Studies  
(n patients) 
Evidence 
certainty 
 Odds 
ratio 
(95% 
CI) 
Absolute 
difference 
 Studies  
(n patients) 
Evidence 
certainty 
 Odds 
ratio 
(95% CI) 
Absolute difference 
Survival with 
favorable 
neurologic 
outcome at 1 
month  
3 (44 698)21,26,32   Very low  1.10  
[1.03, 
1.17]  
9 more per 1000 
(from 3 more to 15 
more) 
2 (6799)21,26   Very low  1.47  
[1.03, 
2.09]  
11 more per 1000  
(from 1 more to 25 
more) 
Survival with 
favorable 
neurologic 
outcome at 
2 (5533)18,22 Very low  1.70  
[1.21, 
2.37]  
14 more per 1000 
(from 4 more to 27 
more) 
1 (5288)18 Very low  1.67  
[1.13, 
2.47]  
14 more per 1000 
(from 3 more to 30 
more) 
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 Unadjusted Analysis Adjusted Analysis 
hospital 
discharge  
Survival at 1 
month  
2 (6799)21,26   Very low  1.20  
[0.99, 
1.45]  
11 more per 1000 
(from 1 fewer to 25 
more) 
2 (6799)21,26 Very low  1.45  
[1.09, 
1.94]  
25 more per 1000 
(from 5 more to 51 
more) 
Survival at 
hospital 
discharge  
7 (14 139)17-
20,23,24,28 
Very low  1.23  
[0.99, 
1.53]  
33 more per 1000 
(from 2 fewer to 73 
more) 
1 (5288)18  Very low  1.33  
[1.07, 
1.66]  
21 more per 1000 
(from 5 more to 42 
more) 
Survival at 
hospital 
admission  
6 (9548)18,20-
22,29,30  
   
Very low  1.08  
[0.95, 
1.23]  
12 more per 1000 
(from 8 fewer to 33 
more) 
1 (2493) 21  Very low  0.97  
[0.70, 
1.34]  
4 fewer per 1000 
(from 39 fewer to 40 
more) 
Return of 
spontaneous 
circulation  
5 (49 229) 
18,20,21,28,32  
Very low  1.17  
[1.08, 
1.27]  
27 more per 1000 
(from 13 more to 
42 more) 
1 (2493)21  Very low  1.14  
[0.88, 
1.48]  
26 more per 1000 
(from 24 fewer to 83 
more) 
CI indicates confidence interval; DA-CPR, dispatcher-assisted cardiopulmonary resuscitation; EMS, emergency medical services. 1 
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 1 
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[h5]Survival With Favorable Neurologic Outcomes. 1 
Six studies involving 50 395 patients reported survival with favorable neurologic outcome at 2 
time points from hospital discharge to 6 months after cardiac arrest.18,21,22,26,28,32 The certainty of 3 
evidence was assessed as very low (downgraded for serious risk of bias, indirectness, and 4 
imprecision).  5 
With the exception reported in 1 small series,28 systems offering DA-CPR were associated with 6 
increased favorable neurologic outcome at 1 month after cardiac arrest and at hospital discharge, 7 
when compared with systems not offering DA-CPR. These effects persisted after adjustment for 8 
confounding variables.  9 
[h5]Survival Including All Neurologic Outcomes. 10 
Nine studies, including 20 938 patients, addressed survival (irrespective of neurologic outcome) 11 
at time points including hospital discharge, 1 month, and 1 year after cardiac arrest.17-21,23,24,26,28 12 
The certainty of evidence for these studies was assessed as very low, downgraded for serious risk 13 
of bias and imprecision. 14 
With the exception reported in a single small series,28 systems offering DA-CPR were associated 15 
with increased survival at 1 month after cardiac arrest and at hospital discharge (Table 3) when 16 
compared with systems not offering DA-CPR. These associations were strengthened after 17 
adjustment for confounding variables. 18 
[h5]Short-Term Survival: Return of Spontaneous Circulation, Hospital Admission. 19 
Eight studies, including 45 474 patients, addressed short-term survival including return of 20 
spontaneous circulation (ROSC) and survival to hospital admission.18,20-22,28-30,32 The certainty of 21 
evidence was assessed as very low, downgraded for serious risk of bias and imprecision. 22 
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With a single exception reported in a small series,21 systems offering DA-CPR were associated 1 
with sustained ROSC but not increased survival to hospital admission (Table 4) when compared 2 
with systems not offering DA-CPR.3 
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Table 4. Bystander Delivery - Comparison of Outcomes From Adults Receiving DA-CPR Versus Those Receiving No 1 
Bystander CPR or Unassisted Bystander CPR 2 
  DA-CPR Versus No CPR (Adjusted Analysis) 
DA-CPR Versus Unassisted Bystander CPR 
(Adjusted Analysis) 
Outcome Studies 
(n patients) 
Evidence 
certainty 
Odds ratio 
(95% CI) 
Studies 
(n patients) 
Evidence 
certainty 
Odds ratio 
(95% CI) 
Survival with favorable 
neurologic outcome at 1 
month  
1 (4306)26   Very low 1.81 
[1.23, 2.67] 
1 (78 112)27   Very low 1.00 
[0.91, 1.10]  
Survival with favorable 
neurologic outcome at 
hospital discharge  
3 (35 921)33-
35 
Very low 1.54  
[1.35, 1.76] 
1 (17 209)34 Very low 1.12  
[0.94, 1.34] 
Survival at 1 month  1 (4306)26   Very low 1.63 
[1.32, 2.01] 
2 (78 697)27,36 Very low 1.13 
[1.06, 1.20]  
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  DA-CPR Versus No CPR (Adjusted Analysis) 
DA-CPR Versus Unassisted Bystander CPR 
(Adjusted Analysis) 
Survival at hospital 
discharge  
5 (43 
550)33,34,37-39 
Very low 1.40 
[1.09, 1.78] 
1 (17 209)34 Very low 0.95  
[0.83, 1.09] 
ROSC at hospital admission  NA NA NA 1 (78 150)27 Very low 1.09 
[1.04, 1.14] 
ROSC  1 (32 506)34 Very low 1.51 
[1.32, 1.73] 
3 (34 811)32,34,36 Very low 1.04 
[0.94, 1.14] 
CI indicates confidence interval; CPR, cardiopulmonary resuscitation; DA-CPR, dispatcher-assisted CPR; NA not applicable; ROSC, 1 
return of spontaneous circulation. 2 
 3 
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[h4]Bystander Delivery: Comparison of Outcomes From Patients Receiving DA-CPR 1 
Versus Those Receiving Either No Bystander CPR or Unassisted Bystander CPR 2 
This evidence evaluation compared outcomes of patients who received bystander CPR as the 3 
result of DA-CPR with 2 groups of patients: (1) those receiving no bystander CPR or (2) those 4 
who received bystander CPR that was performed without dispatch assistance. Twenty 5 
observational cohort studies were identified,21,23,26-28,31-38,40-46 but only 10 of these included 6 
adjusted analysis.26,27,31-38  Because the clinical features of patients who received DA-CPR 7 
differed markedly from both the group that received no CPR and the group that received 8 
bystander CPR without dispatch assistance, only adjusted outcomes are reported. Summary of 9 
the study characteristics and results of the adjusted meta-analysis may be found in Table 4. 10 
[h5]Receipt of DA-CPR Versus No Bystander CPR. 11 
Improvements in survival with favorable neurologic function at hospital discharge31,33,34 and at 1 12 
month26 were reported among patients with OHCA who received bystander DA-CPR compared 13 
with those who received no bystander CPR. In addition, improved survival (regardless of 14 
neurologic status) was reported at hospital discharge31,33,34,37,38 and at 1 month.26 Recipients of 15 
DA-CPR were also more likely to achieve sustained ROSC than those who received no 16 
bystander CPR.34 17 
[h5]Receipt of Bystander CPR With DA-CPR Versus Bystander CPR Without Dispatch 18 
Assistance (ie, Unassisted Bystander CPR). 19 
The findings were inconsistent when comparing patients who received bystander CPR with DA-20 
CPR with patients who received bystander CPR that was performed without dispatch 21 
assistance. Survival with favorable neurologic function did not differ either at hospital 22 
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discharge34 or at 1 month27 between patients who received bystander DA-CPR and those who 1 
received bystander CPR without dispatch assistance. Overall survival at hospital discharge did 2 
not differ between these groups,34 although survival at 1 month favored patients who received 3 
bystander DA-CPR.27,36 Recipients of bystander DA-CPR were also more likely to have ROSC 4 
upon hospital arrival than when bystander CPR was rendered without dispatch assistance.27 5 
Although these studies do not prove equivalence or noninferiority, they suggest that DA-CPR 6 
could possibly be as effective as spontaneously provided (unassisted) CPR. 7 
[h3]Treatment Recommendations 8 
We recommend that emergency medical dispatch centers have systems in place to enable call 9 
handlers to provide CPR instructions for adult patients in cardiac arrest (strong recommendation, 10 
very low certainty evidence).  11 
We recommend that emergency medical call takers provide CPR instructions (when deemed 12 
necessary) for adult patients in cardiac arrest (strong recommendation, very low certainty 13 
evidence). 14 
[h3]Justification and Evidence to Decision Framework Highlights  15 
Whereas the strength of these recommendations is greater than the certainty of the supporting 16 
evidence, taken together, the preponderance of the evidence evaluated in this review suggests 17 
that clinical outcomes after OHCA are more likely to be improved when DA-CPR is available, 18 
offered, and provided. The similarity in outcomes when CPR is initiated spontaneously without 19 
the need for dispatch assistance (perhaps performed by a more skilled or trained bystander) and 20 
when DA-CPR is performed (perhaps with a less skilled or untrained bystander) exemplifies the 21 
potential positive impact of such point-of-care instruction. At a minimum, DA-CPR increases the 22 
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likelihood that bystander CPR will be performed 2, itself an important predictor of favorable 1 
outcome from OHCA.47 The systematic review also found that DA-CPR favored not only 2 
bystander CPR, but time to CPR, ROSC and initial shockable rhythm.2 These considerations, 3 
along with the recognition that randomized clinical trials addressing this question are unlikely to 4 
be forthcoming, led to the task force’s consensus that DA-CPR should be strongly 5 
recommended.   6 
[h3]Knowledge Gaps 7 
This evidence evaluation did not address training, logistical, operational, or economic issues 8 
pertaining to DA-CPR. The task force identified several knowledge gaps requiring further 9 
investigation, including  10 
 Optimal dispatcher training (and retraining) in recognizing OHCA and in providing DA-11 
CPR 12 
 The essential elements of a quality improvement program focused on DA-CPR 13 
 The preferred CPR instruction sequence for DA-CPR 14 
 The potential impact of dispatcher or call-taker’s background or prior experience 15 
(nonhealthcare professional versus paramedic or nurse) on DA-CPR performance 16 
 The role of automated external defibrillators (AEDs) during the course of DA-CPR 17 
 The integration of adjunct technologies (such as artificial intelligence or video) for 18 
clinical decision support 19 
[h1]Advanced Life Support 20 
[h2]Advanced Airway Interventions During Adult Cardiac Arrest  21 
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It is important to identify those airway interventions most likely to improve outcomes for both 1 
OHCA and IHCA. Chest compressions alone do not provide adequate ventilation during 2 
prolonged cardiac arrest. Airway management is therefore required to facilitate ventilation and 3 
reduce the risk of gastric regurgitation and aspiration. The best airway strategy for improving 4 
patient outcomes is uncertain. Based on the evidence available at the time, the 2015 CoSTR 5 
suggested using either an advanced airway or a bag-mask device for airway management during 6 
CPR (weak recommendation, very-low-certainty evidence) for cardiac arrest in any setting.48 7 
Advanced airway management is common during cardiac arrest. The American Heart 8 
Association (AHA) Get With the Guidelines–Resuscitation registry of in-hospital cardiac arrest 9 
(IHCA) reports that 60% to 70% of patients underwent tracheal intubation within the first 15 10 
minutes of cardiac arrest.49 The US Cardiac Arrest Registry to Enhance Survival (CARES) 11 
registry of OHCA50 showed that 52% of patients underwent tracheal intubation, 29% received a 12 
supraglottic airway, and in 18% no advanced airway was inserted. In the recent AIRWAYS-2 13 
RCT (Effect of a Strategy of a Supraglottic Airway Device Versus Tracheal Intubation During 14 
Out-of-Hospital Cardiac Arrest on Functional Outcome),51 which compared i-gel (from 15 
Intersurgical Limited, Berkshire, United Kingdom) with tracheal intubation for OHCA, 17.3% of 16 
patients did not receive an advanced airway. 17 
Since 2015, 3 new RCTs investigating airway management during cardiac arrest have been 18 
published.51-53 This topic was given a high priority for review by the ILCOR ALS Task Force, 19 
and ILCOR commissioned an SR to identify and analyze all published evidence on advanced 20 
airway interventions during OHCA and IHCA.3 The ALS Task Force analyzed and discussed the 21 
SR as well as all of the studies identified by the SR. A draft ALS CoSTR for advanced airway 22 
interventions during cardiac arrest was posted online on March 20, 2019 and included the data 23 
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reviewed and draft treatment recommendations with comments accepted through April 4, 2019. 1 
There were 6798 visits and 16 posted comments during the 2-week comment period. The ALS 2 
Task Force reviewed all comments and, in the light of these, reevaluated and finalized the draft 3 
CoSTR. 4 
[h3]Population, Intervention, Comparator, Outcome, Study Design, and Time Frame  5 
Population: Adults any setting (in-hospital or out-of-hospital) with cardiac arrest from any 6 
etiology 7 
Intervention: A specific advanced airway management method (eg, tracheal intubation or a 8 
supraglottic airway device) during cardiac arrest 9 
Comparators: A different advanced airway management method or no advanced airway 10 
management method (eg, bag-mask ventilation [BMV]) during cardiac arrest 11 
Outcomes: Survival to hospital discharge/28 days with favorable neurological outcome and 12 
survival to hospital discharge/28 days ranked as critical outcomes; ROSC ranked as an important 13 
outcome  14 
Study Designs: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled 15 
before-and-after studies, cohort studies) that compared at least 2 airway strategies eligible for 16 
inclusion; studies with 10 or fewer patients in either group excluded  17 
Time Frame: All years and all languages included; unpublished studies (eg, conference abstracts, 18 
trial protocols) excluded; literature search updated to October 30, 2018 19 
PROSPERO registration: CRD42018115556 20 
[h3]Consensus on Science 21 
Soar 22 
© 2019 American Heart Association, Inc. 
Seventy-one observational studies with 121 combinations of different airway management 1 
strategies were included in the SR.3 Of the 71 comparative studies, 61 included OHCA, 9 2 
included IHCA, and 1 combined both. Because of the risk of bias, heterogeneity between studies, 3 
and the availability of RCTs, no meta-analyses were performed for observational studies.  4 
The SR identified 11 controlled trials of airway management in patients with OHCA.51-61 Of 5 
these, 8 were phase 2/feasibility trials with small sample sizes, generally with a high risk of bias, 6 
including some that were published more than 15 years ago.54-61 Therefore, only 3 trials, all 7 
published in 2018, were used for the SR as they were larger and powered for more relevant 8 
outcomes.51-53 Because of different comparisons and heterogeneity, no meta-analyses of these 9 
RCTs were undertaken (Table 5). 10 
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Table 5. Summary of the Evidence From the 3 RCTs Studying Adult Advanced Airway Management During Cardiac Arrest 1 
Study (First 
Author, Year) 
Intervention Comparator Setting Outcome 
Risk Difference 
(95% CI) 
Certainty in Evidence 
Wang, 201853 Laryngeal tube 
Tracheal 
intubation 
OHCA 
Survival to hospital 
discharge 
27 more per 1000 
(from 6 more to 48 
more) 
 Low in low tracheal intubation 
success setting (OHCA) 
 Very low in high tracheal 
intubation success setting 
(OHCA) 
 Very low (IHCA) 
Wang, 201853 Laryngeal tube 
Tracheal 
intubation 
OHCA 
Survival to hospital 
discharge with a 
favorable 
neurological 
outcome 
21 more per 1000 
(from 3 more to 38 
more) 
 Low in low tracheal intubation 
success setting (OHCA) 
 Very low in high tracheal 
intubation success setting 
(OHCA) 
 Very low (IHCA) 
Benger, 201851  i-gel 
Tracheal 
intubation 
OHCA 
Survival to hospital 
discharge 
4 fewer per 1000 
 Low in low tracheal intubation 
success setting (OHCA) 
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Study (First 
Author, Year) 
Intervention Comparator Setting Outcome 
Risk Difference 
(95% CI) 
Certainty in Evidence 
(from 14 fewer to 8 
more) 
 Very low in high tracheal 
intubation success setting 
(OHCA) 
 Very low (IHCA) 
Benger, 201851 i-gel  
Tracheal 
intubation 
OHCA 
Survival to hospital 
discharge with a 
favorable 
neurological 
outcome 
6 more per 1000 
(from 16 fewer to 4 
more) 
 Low in low tracheal intubation 
success setting (OHCA) 
 Very low in high tracheal 
intubation success setting 
(OHCA) 
 Very low (IHCA) 
Jabre, 201852 
Bag-mask 
ventilation 
Tracheal 
intubation 
OHCA 28-day survival 
1 more per 1000 
(from 18 fewer to 
21 more 
 Low in low tracheal intubation 
success setting (OHCA) 
 Moderate in high tracheal 
intubation success setting 
(OHCA) 
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Study (First 
Author, Year) 
Intervention Comparator Setting Outcome 
Risk Difference 
(95% CI) 
Certainty in Evidence 
 Low (IHCA) 
Jabre, 201852 
Bag-mask 
ventilation 
Tracheal 
intubation 
OHCA 
28-day survival with 
a favorable 
neurological 
outcome 
1 more per 1000 
(from 13 fewer to 
23 more) 
 Low in low tracheal intubation 
success setting (OHCA) 
 Moderate in high tracheal 
intubation success setting 
(OHCA) 
 Low (IHCA) 
CI indicates confidence interval; IHCA, in-hospital cardiac arrest; OHCA, out-of-hospital cardiac arrest; RCT, randomized controlled 1 
trial. 2 
i-gel made by Intersurgical Limited, Berkshire, United Kingdom; Laryngeal Tube made by VBM Medizintechnik GmbH, Sulz am 3 
Neckar, Germany 4 
 5 
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Jabre52 compared BMV with tracheal intubation in a physician-based system whereas Benger 1 
and Wang51,53 compared supraglottic airway devices with tracheal intubation in non–physician-2 
based systems. The tracheal intubation success rates were 98% in the Jabre trial,52 70% in the 3 
Benger trial,51 and 52% in the Wang trial.53 Success rates were not defined identically in the 3 4 
studies; this led to concerns about generalizability of the findings. As a result, the task force 5 
considered 2 different settings when evaluating the overall certainty of evidence (ie, the GRADE 6 
approach): a setting with a low tracheal intubation success rate (similar to the systems in the 7 
Benger51 and Wang53 studies) and a setting with a high tracheal intubation success rate (similar 8 
to the Jabre system52). 9 
Overall there is no high-certainty evidence to recommend an advanced airway strategy over 10 
BMV and no high-certainty evidence to recommend a specific advanced airway device over 11 
another (Table 5). 12 
[h3]Treatment Recommendations 13 
We suggest using bag-mask ventilation or an advanced airway strategy during CPR for adult 14 
cardiac arrest in any setting (weak recommendation, low- to moderate-certainty evidence). 15 
If an advanced airway is used, we suggest a supraglottic airway for adults with OHCA in settings 16 
with a low tracheal intubation success rate (weak recommendation, low certainty of evidence).  17 
If an advanced airway is used, we suggest a supraglottic airway or tracheal intubation for adults 18 
with OHCA in settings with a high tracheal intubation success rate (weak recommendation, very 19 
low certainty of evidence).  20 
If an advanced airway is used, we suggest a supraglottic airway or tracheal intubation for adults 21 
with IHCA (weak recommendation, very low certainty of evidence). 22 
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[h3]Justification and Evidence to Decision Framework Highlights 1 
This topic was given high priority by the ILCOR ALS Task Force. This followed the publication 2 
of 3 new RCTs51-53 since the previous CoSTR in 2015.48,62  3 
The 3 new RCTs have enabled the ALS Task Force to provide more specific treatment 4 
recommendations. The 2015 treatment recommendation was based on evidence only from 5 
observational studies with critical or serious risk of bias primarily caused by confounding and 6 
selection bias. 48,62  7 
There is currently no supporting evidence that an advanced airway (ie, supraglottic airway or 8 
tracheal intubation) during CPR improves survival or survival with a favorable 9 
neurologic/functional outcome after adult cardiac arrest in any setting when compared with 10 
BMV.  11 
This ILCOR 2019 CoSTR addresses airway management during CPR in adults; it does not 12 
address airway management after ROSC. After ROSC, survivors requiring mechanical 13 
ventilation and postresuscitation care will eventually require tracheal intubation. 14 
We have used the term advanced airway strategy because advanced airway device placement 15 
usually starts with a variable period of BMV. The timing and reasons for transitioning to an 16 
advanced airway device will vary based on the clinical scenario. In the 3 recent RCTs,51-53 17 
patients treated with advanced airways had a period of BMV while providers prepared for device 18 
insertion; in some patients, a supraglottic airway was inserted as the first airway intervention 19 
without BMV. The term advanced airway strategy includes all of these options.  20 
We have not provided a precise value or range of values for low and high intubation success rate 21 
or an agreed definition. Studies have used different definitions of tracheal intubation success. We 22 
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considered the Wang and Benger RCTs51,53 as having a low tracheal intubation success rate 1 
(51.6% and 69.8%, respectively) and the Jabre RCT52 as having a high success rate (97.9%).  2 
We assumed that tracheal intubation success rates are high in the in-hospital setting, but there is 3 
limited evidence to support this, and success is likely to be site-dependent. The recommendations 4 
for IHCA are primarily based on indirect evidence from the OHCA studies. There are no airway 5 
RCTs for IHCA, and the task force did consider the findings of 1 large (n=71 615) observational 6 
study of IHCA that tracheal intubation within any given minute during the first 15 minutes of 7 
resuscitation, compared with no intubation during that minute, was associated with decreased 8 
survival to hospital discharge.49 This study used a time-dependent propensity score but did not 9 
eliminate confounding by indication and provided only very-low-certainty evidence.  10 
We have not expressed a preference for a particular supraglottic airway device of those currently 11 
available (the i-gel [from Intersurgical Limited, Berkshire, United Kingdom] was used in the 12 
Benger RCT51 and the Laryngeal Tube [from VBM Medizintechnik GmbH, Sulz am Neckar, 13 
Germany] in the Wang RCT53). The performance of individual supraglottic airway devices 14 
varies, and therefore, we did not pool data from these 2 studies. 15 
BMV can be difficult to perform, and effectiveness varies according to provider skills. We have 16 
not evaluated the optimal bag-mask technique (eg, 1-person or 2-person) and the use of adjuncts 17 
such as oropharyngeal or nasopharyngeal airways.  18 
The task force considered that the preferred airway option is likely to depend on the skills of the 19 
provider and the specific patient circumstances. In addition, patients may require different airway 20 
interventions at different stages of resuscitation. 21 
[h3]ALS Task Force Knowledge Gaps 22 
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The task force identified several knowledge gaps requiring further investigation, including 1 
 A prospective comparison of BMV with supraglottic airway use 2 
 The optimal airway management strategy for IHCA  3 
 The impact on outcome of using an advanced airway (supraglottic airway or tracheal 4 
intubation) without prior BMV 5 
 The optimal supraglottic airway for use during cardiac arrest 6 
 The optimal time point during CPR to change to different airway techniques 7 
 The impact of different airway strategies on CPR quality (no-flow time), and oxygenation 8 
and ventilation during CPR 9 
 The training and clinical experience required to maintain proficiency in an airway 10 
technique 11 
[h2]Use of Vasopressors in Cardiac Arrest  12 
Vasopressors have been used in CPR since animal experiments in the 1960s, despite lack of RCT 13 
evidence in humans at the time.63,64 In the last 20 years, several human RCTs have provided 14 
evidence about vasopressor use for cardiac arrest. ILCOR has reviewed the use of vasopressors 15 
regularly, with the most recent update in 2015.48,62 The ILCOR ALS Task Force targeted the 16 
current update after the 2018 publication of a new large RCT on the use of epinephrine in 17 
OHCA.65 This updated CoSTR summary is derived from an ILCOR-commissioned SR and 18 
meta-analysis completed in 2019.4 The ALS Task Force analyzed and discussed the SR as well 19 
as all of the studies identified by the SR. A draft CoSTR for vasopressors in cardiac arrest was 20 
posted online on March 20, 2019, and included the data reviewed and draft treatment 21 
recommendations with comments accepted through April 4, 2019. This site was viewed 3861 22 
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times during the comment period and 6 comments were posted. The ALS Task Force reviewed 1 
the comments and, in the light of these, reevaluated and finalized the draft CoSTR. 2 
[h3]Population, Intervention, Comparator, Outcome, Study Design, and Time Frame 3 
Population: Adults (>18 years) with cardiac arrest in any setting (out-of-hospital or in-hospital) 4 
Intervention: Vasopressor or a combination of vasopressors provided intravenously or 5 
intraosseously during cardiopulmonary resuscitation 6 
Comparators: No vasopressor, or a different vasopressor, or a combination of vasopressors 7 
provided intravenously or intraosseously during CPR 8 
Outcomes: Short-term survival (ROSC and survival to hospital admission), midterm survival 9 
(survival to hospital discharge, 28 days, 30 days, or 1 month), midterm favorable neurologic 10 
outcomes (Cerebral Performance Category score of 1‒2 or modified Rankin Scale 0‒3 at hospital 11 
discharge, 28 days, 30 days, or 1 month), and long-term unfavorable and poor (modified Rankin 12 
Score 4‒5) neurological outcomes (after 1 month) 13 
Study Designs: Randomized trials, nonrandomized trials, and observational studies (cohort and 14 
case-control studies) with a comparison group included  15 
Time Frame: From inception of databases to November 23, 2018 16 
PROSPERO registration: CRD42018116989 17 
[h3]Consensus on Science 18 
[h4]Epinephrine Compared With Placebo  19 
For the comparison of epinephrine with placebo, there are 2 RCTs with a total of more than 8500 20 
OHCA patients that provide evidence on our critical and important outcomes65,66 but no RCTs of 21 
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IHCA. The PARAMEDIC2 trial (A Randomized Trial of Epinephrine in Out-of-Hospital 1 
Cardiac Arrest) is a recent RCT that randomized approximately 8000 OHCA patients managed 2 
by paramedics in the United Kingdom,65 and the PACA trial (Placebo-Controlled Trial of 3 
Adrenaline in Cardiac Arrest) randomized approximately 500 OHCA patients managed by 4 
paramedics in Western Australia.66 Meta-analysis of these studies was conducted to update the 5 
CoSTR for epinephrine use during CPR.4 6 
The findings of the SR and meta-analysis for all initial rhythms are summarized in Table 6. Only 7 
the most recent study reported on 3-month survival.65 That study found a statistically significant 8 
increase in survival at 3 months in the epinephrine group but no statistical differences in survival 9 
with favorable or unfavorable neurologic outcome at 3 months. The meta-analysis of the 2 10 
studies found no benefit in favorable neurologic outcome at discharge but showed higher rates of 11 
survival to discharge, survival to admission, and ROSC in the epinephrine group.65,66 12 
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Table 6. Relative Risk and Absolute Risk Difference for Each Outcome With Epinephrine Compared With Placebo  1 
Study 
(First Author, Year) 
Outcome 
Relative Risk (95% 
CI) 
Risk Difference (95% CI) 
Certainty in 
Evidence 
Perkins,  
201865 
Favorable neurologic outcome at 
3 months 
1.30 
(0.94‒1.80) 
5 more per 1000 
(from 1 fewer to 13 more) 
Low 
Perkins,  
201865 
Survival at 3 months 
1.40 
(1.07, 1.84) 
9 more per 1000 
(from 2 more to 18 more) 
Moderate 
Jacobs,  
2011 
Perkins, 2018 
65,66 
Favorable neurologic outcome at 
hospital discharge 
1.21 
(0.90‒1.62) 
4 more per 1000 
(from 2 fewer to 12 more) 
Moderate 
Jacobs,  
2011 
Perkins,  
201865,66 
Survival to hospital discharge 
1.44 
(1.11‒1.86) 
10 more per 1000  
(from 2 more to 19 more) 
Moderate 
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Study 
(First Author, Year) 
Outcome 
Relative Risk (95% 
CI) 
Risk Difference (95% CI) 
Certainty in 
Evidence 
Jacobs,  
2011 
Perkins,  
201865,66 
Return of spontaneous 
circulation 
3.09  
(2.82‒3.39) 
243 more per 1000  
(from 211 more to 277 more) 
High 
CI indicates confidence interval. 1 
 2 
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In the subgroup of patients with nonshockable rhythms, combined evidence from the 2 RCTs 1 
showed benefit of epinephrine for survival to discharge (moderate certainty; RR, 2.56; 95% CI, 2 
1.37‒4.80; ARD, 0.6%; 95% CI, 0.1‒1.5) and ROSC (high certainty; RR, 4.45; 95% CI, 3.91‒3 
5.08; ARD, 25.4%; 95% CI, 21‒30). There was no difference in survival to discharge with 4 
favorable neurologic outcome (low certainty).65,66 In data pending publication from the larger, 5 
more recent trial, the subgroup with nonshockable rhythms showed no difference in survival to 3 6 
months with favorable or unfavorable neurologic outcome, although this result approached 7 
significance (very low certainty; RR, 3.03; 95% CI, 0.98‒9.38; ARD, 0.3%; 95% CI, 0‒1.1).65,67 8 
In the subgroup of patients with shockable rhythms, combined evidence from the 2 RCTs 9 
showed benefit of epinephrine for ROSC (moderate certainty; RR, 1.68; 95% CI, 1.48‒1.92; 10 
ARD, 18.5%; 95% CI, 13.0‒25.0) but no difference for survival to discharge.65,66 In data pending 11 
publication from the larger, more recent trial, the subgroup with shockable rhythms showed no 12 
difference in survival to 3 months with favorable neurologic outcome.67 13 
[h4]Vasopressin Compared With Epinephrine 14 
Three RCTs with more than 1500 OHCA patients compared vasopressin with epinephrine; all 15 
were published more than 10 years ago.68-70 The combined results of these studies showed no 16 
benefit of vasopressin compared with epinephrine across all outcomes and initial rhythms.  17 
One RCT included 200 patients with IHCA randomized to vasopressin or epinephrine with any 18 
initial rhythm and showed no benefit from the use of vasopressin compared with epinephrine.71 19 
[h4]Initial Epinephrine Plus Vasopressin Compared With Epinephrine Only  20 
Three RCTs with more than 3000 OHCA patients compared epinephrine plus vasopressin with 21 
epinephrine only; all were published more than 8 years ago.72-74 The combined results of these 22 
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studies showed no benefit across all outcomes and initial rhythms. There were no in-hospital 1 
studies of this comparison.  2 
[h3]Treatment Recommendations 3 
We recommend administration of epinephrine during CPR (strong recommendation, low to 4 
moderate certainty of evidence). 5 
For nonshockable rhythms (pulseless electrical activity [PEA]/asystole), we recommend 6 
administration of epinephrine as soon as feasible during CPR (strong recommendation, very-low 7 
certainty of evidence). 8 
For shockable rhythms (ventricular fibrillation [VF]/ventricular tachycardia [VT]), we suggest 9 
administration of epinephrine after initial defibrillation attempts are unsuccessful during CPR 10 
(weak recommendation, very-low certainty of evidence). 11 
We suggest against the administration of vasopressin in place of epinephrine during CPR (weak 12 
recommendation, very-low certainty of evidence). 13 
We suggest against the addition of vasopressin to epinephrine during CPR (weak 14 
recommendation, low certainty of evidence).  15 
[h3]Justification and Evidence to Decision Framework Highlights 16 
The ILCOR ALS Task Force prioritized this PICOST (population, intervention, comparator, 17 
outcome, study design, time frame) after the recent publication of a large RCT comparing 18 
administration of epinephrine with placebo in over 8000 OHCA patients.65 The collective 19 
evidence from the recent trial and a small earlier RCT showed that epinephrine for OHCA 20 
increases ROSC, survival to discharge, and survival at 3 months but has not been shown 21 
definitively to increase survival to discharge with favorable neurologic outcome.4,65,66 The more 22 
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recent trial, which was also the only one reporting outcomes at 3 months, found no difference in 1 
survival with favorable or unfavorable neurologic outcome at the 3-month time point.65 The lack 2 
of statistical difference in survival with favorable and unfavorable outcome at 3 months may 3 
reflect the low event rates for these outcomes and consequent failure to achieve the optimal 4 
sample size for these outcomes, resulting in low power to detect a difference. The increase in 5 
survival with favorable neurologic outcome at 3 months approaches statistical significance for 6 
nonshockable initial rhythms, with the lower limit of the confidence interval being very close to 7 
1. Whether the difference in neurologic outcome would be larger in a patient population with 8 
higher overall survival than that seen in the PARAMEDIC2 trial is unknown. A very high value 9 
is placed on the apparent life-preserving benefit of epinephrine, even if the absolute effect size is 10 
likely to be small. Although the PARAMEDIC2 study raised concerns by some about increasing 11 
the number of survivors with unfavorable neurologic outcome, the opinion of the ALS task force 12 
is that the data at 3 months do not support this assertion. Overall, the impact of epinephrine 13 
administration on neurologic outcome for patients with OHCA remains uncertain, but the 14 
available data is more suggestive of benefit than harm. Whether the administration of 15 
epinephrine earlier than in the available OHCA trials would have a larger beneficial effect also 16 
remains uncertain but is suggested by observational data. That stated, the ALS Task Force 17 
acknowledged the importance of considering the cost burden incurred with a potential increase in 18 
short-term survival with unfavorable neurologic outcome. Conversely, an increase in ROSC may 19 
allow for the development of other treatments to prevent or mitigate neurologic injury. The 20 
opportunity for families to see patients before death and the possibility for organ donation were 21 
additional potential benefits of the increase in short-term survival that were considered. The task 22 
force recognized that different healthcare systems and different cultures may weigh these costs 23 
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and benefits differently. A formal cost-effectiveness analysis was not performed, and this 1 
remains a knowledge gap. 2 
The use of vasopressin alone or in combination with epinephrine was not shown to be beneficial 3 
when compared with epinephrine alone, and thus epinephrine alone is recommended because it 4 
reduces complexity. 5 
There is a statistically significant benefit of standard dose epinephrine compared with placebo on 6 
survival to hospital discharge in OHCA patients with nonshockable initial rhythms but not in 7 
those with shockable initial rhythms (although epinephrine improved ROSC in all rhythms). As 8 
these are subgroup comparisons, however, and were not separately randomized, the results 9 
should be interpreted with some caution. For example, the lack of a statistically significant 10 
difference in shockable rhythms may result from inadequate power, as there were far fewer 11 
patients in this subgroup than in the nonshockable rhythms groups.  12 
In most cases of nonshockable rhythms, there are limited alternative interventions, and survival 13 
is very poor unless a reversible cause is identified and treated. Therefore, we recommend 14 
provision of epinephrine as soon as feasible in cardiac arrest with nonshockable rhythms. 15 
Exceptions may exist where a clear reversible cause can be addressed rapidly.  16 
The optimal timing for epinephrine in patients with shockable rhythms is unknown. The studies 17 
evaluating administration of epinephrine used protocols for epinephrine administration after the 18 
third shock. The task force agrees that it seems prudent to wait to administer epinephrine until 19 
initial defibrillation attempts have been unsuccessful. However, the optimal timing or number of 20 
shocks after which epinephrine should be administered remains unclear.  21 
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There is also very limited data to guide the specific dosing of epinephrine during 1 
cardiopulmonary resuscitation. The 2 OHCA RCTs comparing epinephrine with placebo used 2 
standard dose epinephrine (1 mg intravenous or intraosseous every 3‒5 minutes). Although this 3 
CoSTR did not separately evaluate high-dose epinephrine because no new evidence was found, a 4 
previous ILCOR review did not find evidence of a survival benefit for high-dose epinephrine, 5 
and thus the evidence to date supports the dosing used in the 2 RCTs included in meta-analysis 6 
in the current review.  7 
There is limited RCT evidence on the use of epinephrine for IHCA. There are no studies on the 8 
use of standard-dose epinephrine compared with placebo in the in-hospital setting and only 1 on 9 
the use of vasopressin compared with epinephrine.75 There was no statistical benefit or harm 10 
from the administration of vasopressin compared with epinephrine for in-hospital CPR. 11 
Therefore, the ILCOR ALS Task Force decided to make the same recommendations for 12 
epinephrine administration for in-hospital and OHCA, based upon the evidence for OHCA.  13 
[h3]ALS Task Force Knowledge Gaps 14 
With the recent publication of a large RCT comparing epinephrine with placebo in OHCA, we 15 
have greater confidence in the benefit of epinephrine for survival to discharge and ROSC. 16 
However, the effect of epinephrine on neurologic outcomes is still uncertain and remains an 17 
important knowledge gap. The task force identified several other knowledge gaps requiring 18 
further investigation, including 19 
 The long-term neurologic benefit of epinephrine in cardiac arrest 20 
 The optimal dose of epinephrine and dosing interval 21 
 Use of and optimal timing of epinephrine administration in patients with shockable 22 
rhythms 23 
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 Use of epinephrine for IHCA  1 
 The cost-effectiveness of epinephrine  2 
 The effect of different routes of administration (intravenous versus intraosseous) 3 
 The effect of increased ROSC on organ donation 4 
 Effective therapies to prevent or mitigate against neurologic injury associated with 5 
cardiac arrest 6 
[h2]ECPR for Cardiac Arrest: Adults 7 
ECPR is used to support circulation in patients with cardiac arrest refractory to conventional 8 
CPR.76 ECPR maintains vital organ perfusion while potential reversible causes of the cardiac 9 
arrest can be identified and treated. ECPR can be considered in select patients, when rapid expert 10 
deployment is possible; however, optimal patient selection and timing of the therapy are not well 11 
defined. An SR was undertaken by ILCOR to assess the effectiveness of ECPR, compared with 12 
manual or mechanical CPR, for OHCA and IHCA of all causes in adults and children.5 A draft 13 
CoSTR posted for public comment was viewed 1169 times in the 2-week comment period. The 14 
Task Force reviewed the 4 posted comments and considered the suggestions when finalizing the 15 
“Justification and Evidence to Decision Highlights” section. 16 
[h3]Population, Intervention, Comparator, Outcome, Study Design, and Time Frame 17 
Population: Adults (≥18 years) and children (<18 years) with cardiac arrest in any setting (out-18 
of-hospital or in-hospital) 19 
Intervention: ECPR, including extracorporeal membrane oxygenation or cardiopulmonary 20 
bypass, during cardiac arrest 21 
Comparator: Manual CPR and/or mechanical CPR 22 
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Outcomes: Clinical outcomes, including short-term survival and neurological outcomes (eg, 1 
hospital discharge, 28 days, 30 days, and 1 month), and long-term survival and neurological 2 
outcomes (eg, 3 months, 6 months, and 1 year) 3 
Study Design: Randomized trials, non-RCTs, and observational studies (cohort studies and case-4 
control studies) with a control group included; animal studies, ecological studies, case series, 5 
case reports, reviews, abstracts, editorials, comments, and letters to the editor not included 6 
Time Frame: All years and all languages included 7 
PROSPERO registration: CRD42018085404 8 
Note: The pediatric information is summarized in a later section of this document (see Pediatric 9 
Life Support, ECPR: Infants and Children) 10 
[h3]Consensus on Science 11 
No randomized clinical trials were identified. Selected summary data are included in Table 7. 12 
Fifteen of the included studies were in adult OHCA.77-91 Three studies included both OHCA and 13 
IHCA patients.78,82,89  Most studies defined the exposure as ECPR use, 1 study85 defined the 14 
exposure as ECPR availability, and 2 studies90,91 defined exposure as an ECPR strategy. Twelve 15 
studies reported survival to hospital discharge,77-85,87-89 6 studies reported long-term 16 
survival,78,81,83,85,87,88 8 studies reported favorable neurologic outcome at hospital discharge,79-17 
81,84,85,87,90,91 and 6 studies reported long-term favorable neurologic outcomes.81,83,85-88  18 
 19 
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Table 7. Summary of Adult ECPR Studies 1 
Study (First 
Author, 
Year) 
Country 
Years of 
Patient 
Inclusion 
IHCA 
Versus 
OHCA 
Inclusion 
Criteria 
Patients 
Analyzed 
(Number) 
Covariates Included 
in Adjusted Analysis 
Hospital Discharge/1 month 
Proportions 
Number (%) 
Adjusted Results 
(OR or RR [95% 
CI]) Exposed Unexposed 
Agostinucci, 
201177 
France 2005‒2010 OHCA Use of load-
distributing band  
285 NA 0/27 (0) 3/258 (1) NR 
Blumenstein, 
201592 
Germany 2009‒2013 IHCA Cardiovascular 
admission, 
witnessed 
353 Age, APACHE II 
score, CPR duration, 
obesity, dyslipidemia, 
coronary artery 
disease, lactate, 
creatine kinase, 
eGFR, creatinine, 
ICU, OR, dose of 
norepinephrine  
14/52 (27) 9/52 (17) 1.76 (0.68, 4.53) 
[Calculated] 
Cesana, 
201878 
Italy 2011‒2015 Combined Age 18‒75 
years, witnessed, 
148 NA 13/63 (21) 49/85 (58) NR 
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Study (First 
Author, 
Year) 
Country 
Years of 
Patient 
Inclusion 
IHCA 
Versus 
OHCA 
Inclusion 
Criteria 
Patients 
Analyzed 
(Number) 
Covariates Included 
in Adjusted Analysis 
Hospital Discharge/1 month 
Proportions 
Number (%) 
Adjusted Results 
(OR or RR [95% 
CI]) Exposed Unexposed 
proven ischemic 
etiology, absence 
of severe 
comorbidities 
that would have 
precluded ICU 
admission and 
conditioning in 
the short-term 
prognosis 
Chen, 200893 Taiwan 2004‒2006 IHCA Age 18‒75 
years, CPR for 
>10 min, cardiac 
origin, witnessed 
92 Age, sex, initial 
cardiac rhythm, time 
point of CPR, CPR 
15/46 (33) 8/46 (17) 2.30 (0.86, 6.13) 
[Calculated] 
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Study (First 
Author, 
Year) 
Country 
Years of 
Patient 
Inclusion 
IHCA 
Versus 
OHCA 
Inclusion 
Criteria 
Patients 
Analyzed 
(Number) 
Covariates Included 
in Adjusted Analysis 
Hospital Discharge/1 month 
Proportions 
Number (%) 
Adjusted Results 
(OR or RR [95% 
CI]) Exposed Unexposed 
duration, 
comorbidities 
Cho, 201494 Korea 2001‒2013 IHCA Pulmonary 
embolism 
20 Hypertension, CPR 
duration 
NR NR NR 
Choi, 201679 Korea 2011‒2015 OHCA Nontraumatic, 
age ≤75 years, 
witnessed 
cardiac arrest, 
bystander 
administration of 
CPR or no-flow 
time ≤5 min, 
prehospital low-
flow time ≤30 
60 NA 3/10 (30) 4/50 (8) NR 
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Study (First 
Author, 
Year) 
Country 
Years of 
Patient 
Inclusion 
IHCA 
Versus 
OHCA 
Inclusion 
Criteria 
Patients 
Analyzed 
(Number) 
Covariates Included 
in Adjusted Analysis 
Hospital Discharge/1 month 
Proportions 
Number (%) 
Adjusted Results 
(OR or RR [95% 
CI]) Exposed Unexposed 
min and 
refractory arrest 
>10 min of 
conventional 
CPR at the ED, 
known absence 
of severe 
comorbidities 
that preclude 
admission to the 
intensive care 
unit 
Chou, 2014 Taiwan 2006‒2010 IHCA Age >18 years, 
acute myocardial 
66 NA NR NR 1.93 (0.60, 6.23) 
[Unadjusted] 
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Study (First 
Author, 
Year) 
Country 
Years of 
Patient 
Inclusion 
IHCA 
Versus 
OHCA 
Inclusion 
Criteria 
Patients 
Analyzed 
(Number) 
Covariates Included 
in Adjusted Analysis 
Hospital Discharge/1 month 
Proportions 
Number (%) 
Adjusted Results 
(OR or RR [95% 
CI]) Exposed Unexposed 
infarction in the 
ED, CPR for >10 
min 
Hase, 200580 Japan 1999‒2003 OHCA Presumed 
cardiac etiology 
100 NA 13/38 (34) 27/62 (44) NR 
Kim, 201481 Korea 2006‒2013 OHCA Age >18 years, 
not traumatic 
104 Age, sex, comorbidity 
score, bystander CPR, 
witnessed cardiac 
arrest, first 
documented arrest 
rhythm, presumed 
etiology of arrest, 
interval from arrest to 
CPR started by EMS 
9/52 (17) 11/52 (21) 0.78 (0.29, 2.08) 
[Calculated] 
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Study (First 
Author, 
Year) 
Country 
Years of 
Patient 
Inclusion 
IHCA 
Versus 
OHCA 
Inclusion 
Criteria 
Patients 
Analyzed 
(Number) 
Covariates Included 
in Adjusted Analysis 
Hospital Discharge/1 month 
Proportions 
Number (%) 
Adjusted Results 
(OR or RR [95% 
CI]) Exposed Unexposed 
provider, CPR 
duration, and 
therapeutic 
hypothermia 
Lee, 201582 Korea 2009‒2014 Combined NR 955 Age, main diagnosis, 
location, CPR 
duration, initial 
rhythm, hypertension, 
malignancy, stroke, 
chronic renal failure, 
cardiovascular 
disease  
18/81 (22) 120/874 
(14) 
0.37 (0.13, 1.06) 
Lin, 201095 Taiwan 2004‒2006 IHCA Age 18‒75 
years, cardiac 
54 Age, sex, initial 
rhythm, CPR 
8/27 (30) 5/27 (19) 1.85 (0.52, 6.63) 
[Calculated] 
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Study (First 
Author, 
Year) 
Country 
Years of 
Patient 
Inclusion 
IHCA 
Versus 
OHCA 
Inclusion 
Criteria 
Patients 
Analyzed 
(Number) 
Covariates Included 
in Adjusted Analysis 
Hospital Discharge/1 month 
Proportions 
Number (%) 
Adjusted Results 
(OR or RR [95% 
CI]) Exposed Unexposed 
origin, CPR 
duration >10 
min, ROSC 
duration, timing and 
location, 
comorbidities 
(diabetes, 
hypertension, 
dyslipidemia, 
malignancy, COPD, 
cardiovascular or 
cerebrovascular, 
abnormal liver 
function, dialysis) 
Maekawa, 
201383 
Japan 2000‒2004 OHCA Presumed 
cardiac etiology, 
age >16 years, 
48 Not clear, but 
probably: Age, sex, 
activities of daily 
9/24 (38) 3/24 (13) 4.20 (0.97, 18.2) 
[Calculated] 
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Study (First 
Author, 
Year) 
Country 
Years of 
Patient 
Inclusion 
IHCA 
Versus 
OHCA 
Inclusion 
Criteria 
Patients 
Analyzed 
(Number) 
Covariates Included 
in Adjusted Analysis 
Hospital Discharge/1 month 
Proportions 
Number (%) 
Adjusted Results 
(OR or RR [95% 
CI]) Exposed Unexposed 
witnessed, CPR 
duration >20 min 
living, location of 
OHCA, bystander 
CPR, initial rhythm, 
number of shocks, 
airway insertion, 
venous access, 
physician-staffed 
ambulance, ROSC 
during transport, 
times, TTM, IABP, 
PCI, CPR duration, 
time from arrest to 
advanced life support 
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Study (First 
Author, 
Year) 
Country 
Years of 
Patient 
Inclusion 
IHCA 
Versus 
OHCA 
Inclusion 
Criteria 
Patients 
Analyzed 
(Number) 
Covariates Included 
in Adjusted Analysis 
Hospital Discharge/1 month 
Proportions 
Number (%) 
Adjusted Results 
(OR or RR [95% 
CI]) Exposed Unexposed 
Poppe, 
201584 
Austria 2013‒2014 OHCA Age >18 years, 
ongoing CPR 
96 NA 2/12 (17) 8/84 (10) NR 
Sakamoto, 
201485 
Japan 2008‒2011 OHCA Shockable 
rhythm, cardiac 
arrest on arrival, 
within 45 min 
from reception 
of the emergency 
call or the onset 
of cardiac arrest 
to the hospital 
arrival, no ROSC 
at least during 
454 NA 69/260 
(27) 
12/193 (6) NR 
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Study (First 
Author, 
Year) 
Country 
Years of 
Patient 
Inclusion 
IHCA 
Versus 
OHCA 
Inclusion 
Criteria 
Patients 
Analyzed 
(Number) 
Covariates Included 
in Adjusted Analysis 
Hospital Discharge/1 month 
Proportions 
Number (%) 
Adjusted Results 
(OR or RR [95% 
CI]) Exposed Unexposed 
the 15 min after 
hospital arrival  
Schober, 
201786 
Austria 2002‒2012 OHCA Cardiac origin, 
CPR duration 
>30 min 
239 NA NR NR NR 
Shin, 201196, 
Shin, 201398 
Korea 2003‒2009 IHCA Age 18‒80 
years, CPR 
duration >10 
min, witnessed 
120 Age, sex, 
comorbidities, 
clinical situation, 
cause of the arrest, 
location, year, time 
during day and week, 
initial rhythm, CPR 
duration, prearrest 
SOFA score, Deyo-
19/60 (32) 6/60 (10) 4.17 (1.53, 11.4) 
[Calculated] 
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Study (First 
Author, 
Year) 
Country 
Years of 
Patient 
Inclusion 
IHCA 
Versus 
OHCA 
Inclusion 
Criteria 
Patients 
Analyzed 
(Number) 
Covariates Included 
in Adjusted Analysis 
Hospital Discharge/1 month 
Proportions 
Number (%) 
Adjusted Results 
(OR or RR [95% 
CI]) Exposed Unexposed 
Charlson score, post-
CPR variables 
Siao, 201587 Taiwan 2011‒2013 OHCA Age 18‒75 
years, ventricular 
fibrillation, no-
flow <5 min, 
refractory 
cardiac arrest 
60 Age, CPR duration, 
defibrillation, female 
gender, use of 
therapeutic 
hypothermia 
10/20 (50) 11/60 (28) 4.10 (0.79, 21.3) 
Tanno, 
200888 
Japan 2000‒2004 OHCA Age >16 years, 
cardiac origin 
398 NA 14/66 (21) 25/332 (8) NR 
Venturini, 
201789 
United 
States 
2011‒2016 Combined CPR in cardiac 
catheterization 
laboratory, 
31 NA 1/14 (7) 3/17 (18) NR 
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Study (First 
Author, 
Year) 
Country 
Years of 
Patient 
Inclusion 
IHCA 
Versus 
OHCA 
Inclusion 
Criteria 
Patients 
Analyzed 
(Number) 
Covariates Included 
in Adjusted Analysis 
Hospital Discharge/1 month 
Proportions 
Number (%) 
Adjusted Results 
(OR or RR [95% 
CI]) Exposed Unexposed 
mechanical chest 
compression 
Yannapoulos
, 201690 
United 
States 
2015‒2016 OHCA Age 18‒75 
years, cardiac 
etiology, initial 
shockable 
rhythm, 
minimum 3 
direct-current 
shocks without 
ROSC, received 
amiodarone 300 
mg, eligible for 
mechanical CPR, 
188 NA 10/18 (53) NR NR 
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Study (First 
Author, 
Year) 
Country 
Years of 
Patient 
Inclusion 
IHCA 
Versus 
OHCA 
Inclusion 
Criteria 
Patients 
Analyzed 
(Number) 
Covariates Included 
in Adjusted Analysis 
Hospital Discharge/1 month 
Proportions 
Number (%) 
Adjusted Results 
(OR or RR [95% 
CI]) Exposed Unexposed 
transfer time 
from scene to 
catheterization 
laboratory <30 
min  
Yannapoulos
, 201791 
United 
States 
2015‒2016 OHCA Age 18‒75 
years, cardiac 
etiology, initial 
shockable 
rhythm, 
minimum 3 
direct-current 
shocks without 
ROSC, received 
232 NA 28/62 (45) NR NR 
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Study (First 
Author, 
Year) 
Country 
Years of 
Patient 
Inclusion 
IHCA 
Versus 
OHCA 
Inclusion 
Criteria 
Patients 
Analyzed 
(Number) 
Covariates Included 
in Adjusted Analysis 
Hospital Discharge/1 month 
Proportions 
Number (%) 
Adjusted Results 
(OR or RR [95% 
CI]) Exposed Unexposed 
amiodarone 300 
mg, eligible for 
mechanical CPR, 
transfer time 
from scene to 
catheterization 
laboratory <30 
min  
APACHE II indicates Acute Physiology, Age, Chronic Health Evaluation II; CI, confidence interval; COPD, chronic obstructive 1 
pulmonary disorder; CPR, cardiopulmonary resuscitation; ED, emergency department; eGFR, estimated glomerular filtration rate; 2 
IABP, intra-aortal balloon pump; ICU, intensive care unit; IHCA, in-hospital cardiac arrest; NA, not applicable; OHCA, out-of-3 
hospital cardiac arrest; OR, odds ratio; PCI, percutaneous intubation; ROSC, return of spontaneous circulation; RR, relative risk; 4 
SOFA, sequential organ failure assessment; TTM, targeted temperature management.  5 
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Seven of the included studies were in adult IHCA.92-98 Most of these studies defined the exposure 1 
as ECPR use, although 2 studies96,98defined the exposure as ECPR attempt. Six studies reported 2 
survival to hospital discharge,92,93,95-98 6 studies reported long-term survival, 92,93,95-98 5 studies 3 
reported favorable neurologic outcome at hospital discharge,92,93,95,96,98 and 5 studies reported 4 
long-term favorable neurologic outcome.92,93,95,96,98 Four studies reported survival analyses with 5 
length of follow-up ranging from 1 to 3 years. 92-95  6 
For studies in both OHCA and IHCA, the overall certainty of evidence was rated as very low for 7 
all outcomes. Individual studies were all at a very serious risk of bias, mainly because of 8 
confounding. Because of this confounding and a high degree of heterogeneity, no meta-analyses 9 
could be performed, and individual studies are difficult to interpret.  10 
[h3]Treatment Recommendations 11 
We suggest ECPR may be considered as a rescue therapy for selected patients with cardiac arrest 12 
when conventional cardiopulmonary resuscitation is failing in settings where this can be 13 
implemented (weak recommendation, very-low certainty of evidence). 14 
[h3]Justification and Evidence to Decision Highlights 15 
In making this weak recommendation, we have considered the extremely high mortality rate of 16 
patients with cardiac arrest, particularly when the arrest is refractory to standard ACLS 17 
interventions (ie, cardiac arrest where conventional CPR is failing). Therefore, the potential for 18 
benefit and value of this intervention remains despite the overall low certainty of supporting 19 
evidence and lack of randomized trials.  20 
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The published studies used select patients for ECPR and not the general population of all cardiac 1 
arrest cases. Guidelines for ECPR use in clinical practice should ideally apply to similar 2 
populations, although RCTs have not been performed to define the optimal population.  3 
We acknowledge that ECPR is a complex intervention that requires considerable resources and 4 
training that are not universally available, but we also acknowledge the value of an intervention 5 
that may be successful in individuals where usual CPR techniques have failed. ECPR can sustain 6 
perfusion while another intervention such as coronary angiography and percutaneous coronary 7 
intervention can be performed. 8 
[h3]ALS Task Force Knowledge Gaps 9 
There are currently no published randomized trials of ECPR, although several are pending. The 10 
task force identified several knowledge gaps requiring further investigation, including 11 
 The optimal post-cardiac arrest care strategy for patients resuscitated using ECPR  12 
 The patient groups that are most likely to benefit from ECPR  13 
 The optimal ECPR techniques  14 
 The optimal timing to initiate ECPR during resuscitation (ie, early, late, when in the 15 
sequence)  16 
 The potential role of ECPR during the periarrest period 17 
 The population-specific differences in indications for ECPR for IHCA and OHCA  18 
 The differences in quality of life (QoL) between survivors of ECPR versus survivors of 19 
conventional CPR  20 
 The cost-effectiveness of ECPR 21 
[h1]Pediatric Life Support 22 
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The Pediatric Life Support Task Force reviewed 4 topics for this 2019 CoSTR: dispatch 1 
instruction in CPR (DA-CPR), advanced airway interventions in pediatric cardiac arrest, 2 
extracorporeal membrane oxygenation CPR (ECPR), and TTM during post–cardiac arrest care. 3 
An SR was published for each of these topics.2,5-7 The Pediatric Life Support Task Force then 4 
reviewed the SR as well as the studies identified by the SR and generated a CoSTR that was 5 
posted on the ILCOR website for public comments for each topic. This document contains a 6 
summary of the 4 CoSTRs, including information about task force deliberations and insights. 7 
[h2]Dispatcher Instruction in CPR: DA-CPR—Pediatrics 8 
ILCOR commissioned an SR to identify and analyze all published evidence reporting outcomes 9 
of offering DA-CPR for OHCA in infants and children.2 The Pediatric Life Support Task Force 10 
analyzed and discussed the SR as well as all of the studies identified by the SR, developed a draft 11 
CoSTR, and posted it online for public comment.15 The draft CoSTR was visited 1736 times 12 
during the 2-week comment period. The task force reviewed the 2 posted comments; both 13 
endorsed the summary of science and treatment recommendation.  14 
The emergency medical dispatcher is an essential link in the chain of survival. In addition to 15 
dispatching EMS resources to medical emergencies, the EMS dispatchers are increasingly being 16 
trained to recognize cardiac arrest, assist bystanders in initiating resuscitation, and support 17 
bystanders in optimizing resuscitation efforts. The international community is continuing to 18 
explore ways to increase bystander CPR for cardiac arrests. One such strategy involves 19 
dispatchers providing CPR instruction to callers/bystanders: DA-CPR. For such a strategy to be 20 
successful, it requires (1) the EMS system to be configured to support the dispatcher to offer 21 
DA-CPR and (2) the bystander to deliver CPR with support from the dispatcher. 22 
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This COSTR explores the impact of DA-CPR on survival and neurologic outcomes after OHCA 1 
in infants and children. 2 
[h3]Population, Intervention, Comparator, Outcome, Study Design, and Time Frame 3 
Population: Infants and children with presumed cardiac arrest in out-of-hospital settings  4 
Intervention: Patients/cases or EMS systems where dispatch assisted CPR is offered  5 
Comparators: Studies with comparators where either systems or specific cardiac arrest cases are 6 
not offered dispatch-assisted CPR  7 
Outcomes (critical outcomes included): Survival with favorable neurologic function (at hospital 8 
discharge, 1 month, or 6 months), survival (hospital discharge, 1 month, or 1 year), short-term 9 
survival (ROSC, hospital admission), provision of bystander CPR; important outcomes were 10 
initial shockable rhythm, time to CPR  11 
Study Designs: RCTs and non-randomized studies (non-RCTs, interrupted time series, controlled 12 
before-and-after studies, cohort studies) eligible for inclusion.  13 
Time Frame: All years and all languages included with the last search performed July 1, 2018; 14 
ongoing or unpublished studies identified through a search of ClinicalTrials.gov online registry16  15 
PROSPERO registration: CRD42018091427 16 
[h3]Consensus on Science 17 
Four studies were included in the SR comparing the outcomes for children with OHCA when 18 
bystanders were offered DA-CPR.25,26,39,99 All the studies were cohort studies of registry data: 2 19 
from the same registry in Japan and 2 from the same registry in Korea. When the overlapping 20 
populations from the same source (registry) were reported for the same outcome, the larger of the 21 
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2 studies was used in the analysis.26,39 The studies by Goto and colleagues26 and Chang and 1 
colleagues39 included adjusted analyses.  2 
There were 2 major groups for outcome comparisons: 3 
 Those patients from systems that included DA-CPR compared with those from systems 4 
that offered no dispatcher CPR assistance; in one of the studies, 25% of bystanders who 5 
were offered dispatcher CPR assistance did not actually provide CPR.26 6 
 Those patients who actually received D-CPR compared with those who did not receive 7 
DA-CPR; the group that did not receive DA-CPR was subdivided into those who 8 
received unassisted CPR and those who received no CPR.  9 
Because all studies that the task force evaluated were nonrandomized, any reported findings must 10 
be considered as occurring in association with the CPR (the intervention) provided, rather than as 11 
caused by it. 12 
[h4]Cardiac Arrest Outcomes in EMS Systems With and Without DA-CPR 13 
One study from the All-Japan Utstein Registry26 reported neurologic outcome at 1 month in a 14 
cohort of 4306 infants and children with OHCA. There was no association in either adjusted or 15 
unadjusted analysis between favorable neurologic outcome at 1 month and systems offering DA-16 
CPR when compared with such outcomes in systems not offering DACPR. The same study from 17 
Japan did not document any association between improved survival at 1 month and DA-CPR in 18 
the unadjusted analysis, but such an association was suggested in the adjusted analysis. In a 19 
separate analysis, there was no association between the incidence of shockable pediatric arrest 20 
rhythms and systems offering DA-CPR.26 21 
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Three studies examined the delivery of bystander CPR in systems that offered DA-CPR 1 
compared with those that did not. In addition to the Goto All-Japan study,26 2 studies25,31 2 
included unadjusted analysis of 3309 children with OHCA. These studies reported a significantly 3 
higher rate of CPR in the cohorts offered DA-CPR in both unadjusted and adjusted analyses. In 4 
addition, the Goto All-Japan study reported earlier time to CPR initiation associated with 5 
systems that offered DA-CPR when compared with those that did not.26 For additional 6 
information, see Table 8.7 
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Table 8. Comparison of Outcomes of Infants and Children with Out-of-Hospital Cardiac Arrest in EMS Systems With and Without 1 
DA-CPR Programs (ie, DA-CPR Offered Versus Not Offered)  2 
Outcomes (Importance) 
Participants 
(Studies), n 
Certainty of 
Evidence (GRADE) 
OR or RR (95% CI)* RD With DA-CPR and No DA-CPR 
Survival with favorable 
neurologic outcome at 1 month 
(critical) 
4306 (1 cohort 
study)26 
Very low  RR: 1.03 (0.73‒1.46) 1 more per 1000 (8 fewer to 14 more) 
ORadj :1.45 (0.98‒2.15), P=0.06 
Survival to 1 month (critical) 4306 (1 cohort 
study)26 
Very low  RR: 1.15 (0.95‒1.40) 14 more per 1000 (4 fewer to 35 more) 
ORadj :1.46 (1.05‒2.03), P=0.02 
Delivery of bystander CPR 
(critical) 
3309 (2 studies)25,31 Low  RR: 2.25 (2.05‒2.47) 315 more per 1000 (188 more to 437 
more) 
4306 (1 cohort 
study)26 
Moderate ORadj : 7.51 (6.58‒8.57), P<0.0001  
Shockable initial rhythm 
(important) 
4306 (1 cohort 
study)26 
Very low RR: 0.82 (0.61‒1.10) 8 fewer per 1000 (5 more to 18 fewer) 
Arrest to CPR initiation 
(important) 
4306 (1 cohort 
study)26 
Very low Shorter time to CPR: median time 4 min IQR (1,9 min) with DA-CPR 
versus 11 min IQR (7,16 min); P<0.000 
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CPR indicates cardiopulmonary resuscitation; DA-CPR, dispatcher-assisted CPR; GRADE, Grading of Recommendations, 1 
Assessment, Development, and Evaluation.; EMS, emergency medical services; IQR, interquartile range; OR, odds ratio; RD, risk 2 
difference; RR, relative risk. 3 
*Relative risks are presented for unadjusted analyses and odds ratios are presented for adjusted analyses. 4 
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[h4]Cardiac Arrest Outcomes in Infants and Children with Out-of-Hospital Cardiac Arrest 1 
Who Received Bystander DA-CPR Compared With Those Who Received No CPR 2 
Goto and colleagues26 and Chang and colleagues39 both reported the association of significantly 3 
improved neurologic outcomes and DA-CPR, when compared with no CPR. In both unadjusted 4 
and adjusted data from the Goto series,26 there were significantly higher rates of favorable 5 
neurologic outcome (Cerebral Performance Category [CPC] 1 and 2) at 1 month associated with 6 
those who received DA-CPR compared with those who received no CPR. There were also 7 
significantly higher rates of survival to 1 month in the DA-CPR cohort in both unadjusted and 8 
adjusted analyses.26 In both adjusted and unadjusted analyses, Chang’s observational study of 9 
1661 children with OHCA reported an association between significantly improved likelihood of 10 
favorable neurologic outcome at hospital discharge as well as survival to hospital discharge and 11 
DA-CPR when compared with no CPR.39 For further information, see Table 9. 12 
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Table 9. Comparison of Outcomes of Infants and Children with Out-of-Hospital Cardiac Arrest Who  Received Bystander 1 
DA-CPR Compared With Those Who Received No CPR  2 
Outcomes (Importance) 
Participants 
(Studies), n 
Certainty of 
Evidence 
(GRADE) 
OR or RR (95% CI)* RD With DA-CPR and No CPR 
Survival with favorable 
neurologic outcome at 1 
month (critical) 
4306 
(1 cohort study)26 
Very low  RR: 1.47(1.05‒2.07) 12 more per 1000 (1 more to 26 more) 
ORadj:1.81 (1.23‒2.67); P=0.003 
Survival with favorable 
neurologic outcome at 
hospital discharge (critical) 
1661 
(1 cohort study)39 
Low  RR: 3.43(2.10‒5.59) 54 more per 1000 (25 more to 99 more) 
ORadj: 2.22 (1.27‒3.88); P=0.005 
Survival at 1 month 
(critical) 
4306 
(1 cohort study)26 
Very low  RR: 1.38(1.15‒1.65) 31 more per 1000 (12 more to 53 more) 
ORadj: 1.63 [1.32‒2.01]; P<0.0001 
Survival to hospital 
discharge (critical) 
1661 
(1 cohort study)39 
Moderate  RR: 2.87(2.02‒4.06) 84 more per 1000 (47 more to 132 more) 
Low ORadj: 2.23 (1.47‒3.38); P=0.002 
Sustained ROSC (critical) 1661 
(1 cohort study)39 
Very low  RR: 2.68(1.94‒3.70) 89 more per 1000 (51 more to 137 more) 
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Outcomes (Importance) 
Participants 
(Studies), n 
Certainty of 
Evidence 
(GRADE) 
OR or RR (95% CI)* RD With DA-CPR and No CPR 
Shockable initial rhythm 
(important) 
5967 
(2 cohort studies)26,39 
Very low RR: 1.52 [0.81‒2.86] 26 more per 1000 (10 fewer to 89 more) 
Arrest to CPR initiation 
(important) 
4306 
(1 cohort study)26 
Very low Shorter time with DA-CPR: median 1 min [IQR 0‒5 min] versus 11 min [IQR 
7‒15] 
1265 
(1 cohort study)31 
Shorter time with DA-CPR: median 4 min [IQR 0‒13 min] versus 10 min 
[IQR 6‒18] P=0.01 
CPR indicates cardiopulmonary resuscitation; DA-CPR, dispatcher-assisted CPR; GRADE, Grading of Recommendations, 1 
Assessment, Development, and Evaluation.; EMS, emergency medical services; IQR, interquartile range; OR, odds ratio; RD, risk 2 
difference; RR, relative risk. 3 
*Relative risks are presented for unadjusted analyses and odds ratios are presented for adjusted analyses. 4 
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In comparisons of infants and children receiving DA-CPR with those receiving unassisted 1 
bystander CPR, Goto reported lower rates of favorable neurologic outcome and survival at 1 2 
month in the DA-CPR group.26 Chang, however, found no difference in either survival or 3 
favorable outcome at discharge between those receiving DA-CPR and those receiving unassisted 4 
bystander CPR.39 Chang did report an increase in rates of sustained ROSC associated with DA-5 
CPR when compared with no CPR, but documented no such increase when comparing those who 6 
received DA-CPR with those who received unassisted bystander CPR.39 7 
The Goto and Chang studies both examined presence of a shockable rhythm as an outcome. The 8 
pooled data did not document an association between an increased presence of shockable rhythm 9 
and receipt of DA-CPR, compared with those who received no CPR, and there was a negative 10 
association when those receiving DA-CPR were compared with those receiving unassisted 11 
CPR.26,39  12 
Not surprisingly, Goto and Chang reported an association between DA-CPR and shorter times to 13 
CPR initiation, when compared with the no bystander CPR group. These 2 studies, however, 14 
reported that time to CPR initiation was longer in the DA-CPR than in the unassisted bystander 15 
CPR cohort.26,39 See Table 10 for further information.16 
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Table 10. Outcomes of Infants and Children with Out-of-Hospital Cardiac Arrest Who Received Bystandaer DA-CPR 1 
Compared With Those Who Received Unassisted Bystander CPR  2 
Outcomes (Importance) 
Participants 
(Studies), n 
Certainty of 
Evidence 
(GRADE) 
RR  
(95% CI)* 
RD With DA-CPR and Unassisted CPR 
Survival with favorable 
neurologic outcome at 1 
month (critical) 
2722 
(1 cohort study)26 
Very low  RR: 0.59 (0.41‒
0.84) 
26 fewer per 1000 (9 fewer to 37 fewer) 
Survival with favorable 
neurologic outcome at 
hospital discharge (critical) 
970 
(1 cohort study)39 
Very low  RR: 0.97 (0.61‒
1.56) 
2 fewer per 1000 (32 fewer to 43 more) 
Survival at 1 month 
(critical) 
2722 
(1 cohort study)26 
Very low  RR:0.77 (0.62‒
0.95) 
34 fewer per 1000 (6 fewer to 57 fewer) 
Survival at hospital 
discharge (critical) 
1661 
(1 cohort study)39 
Very low  RR: 0.99 (0.69‒
1.41) 
2 fewer per 1000 (42 fewer to 51 more) 
Sustained ROSC (critical) 1661 
(1 cohort study)39 
Very low  RR: 0.84 (0.62‒
1.16) 
26 fewer per 1000 (26 more to 66 fewer) 
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Outcomes (Importance) 
Participants 
(Studies), n 
Certainty of 
Evidence 
(GRADE) 
RR  
(95% CI)* 
RD With DA-CPR and Unassisted CPR 
Shockable initial rhythm 3692 
(2 cohort studies)26,39 
Very low RR: 0.54 (0.35‒
0.82) 
61 fewer per 1000 
(31 fewer to 83 fewer) 
Arrest to CPR initiation 2722 
(1 cohort study)26 
Very low Longer time with DA-CPR: median 4 min [IQR 0‒13 min] versus 1 min 
[IQR 0‒5]  
766 
(1 cohort study)31 
Very low Longer time with DA-CPR: median 4 min [IQR 0‒13 min] versus 2 min 
[IQR 0‒10] 
CPR indicates cardiopulmonary resuscitation; DA-CPR, dispatcher-assisted CPR; GRADE, Grading of Recommendations, 1 
Assessment, Development, and Evaluation.; EMS, emergency medical services; IQR, interquartile range; RD, risk difference; ROSC, 2 
return of spontaneous circulation; RR, relative risk. 3 
*Relative risks are presented for unadjusted analyses and odds ratios are presented for adjusted analyses. 4 
 5 
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[h3]Treatment Recommendations 1 
We recommend emergency medical dispatch centers offer dispatch CPR instruction (DA-CPR) 2 
for presumed pediatric cardiac arrest (strong recommendation, very-low-certainty evidence). 3 
We recommend emergency dispatchers provide CPR instruction for pediatric cardiac arrest when 4 
no bystander CPR is in progress (strong recommendation, very-low-certainty evidence). 5 
We cannot make a recommendation for or against emergency dispatch provision of CPR 6 
instructions for pediatric cardiac arrest when bystander CPR is already in progress (no 7 
recommendation, very-low-certainty evidence). 8 
[h3]Justification and Evidence to Decision Framework Highlights  9 
This topic was prioritized by the Pediatric Life Support Task Force after publication of several 10 
new studies since the previous pediatric SR was published in 2011. The 2011 review found 11 
limited evidence to support DA-CPR.100 In considering the importance of this topic, the Pediatric 12 
Life Support Task Force noted that bystander CPR significantly improves the likelihood of 13 
survival from OHCA, but bystander CPR rates remain very low.101 14 
 In developing the CoSTR, the Pediatric Life Support Task Force agreed that consideration 15 
of both unadjusted and adjusted analyses was essential to adequately evaluate the published 16 
evidence. We recognize that unadjusted analysis might be confounded by temporal changes 17 
and systematic and patient care differences between and within EMS systems. 18 
In making a strong recommendation for dispatch centers to offer DA-CPR despite very-low-19 
certainty evidence, the Pediatric Life Support Task Force considered the benefit for the critical 20 
outcome of survival in the adjusted analyses as well as the large positive effect of increased 21 
bystander CPR and reduced time to initiation of CPR when DA-CPR was offered. 22 
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Implementation of DA-CPR appears to be acceptable and feasible, as many EMS systems have 1 
demonstrated. However, its cost effectiveness and impact on health equity have not been 2 
evaluated and, until documented, may present barriers to implementation in under-resourced 3 
regions. Also, successful implementation of any program of DA-CPR requires a process of 4 
continuous quality improvement to ensure that dispatchers can quickly identify a likely cardiac 5 
arrest and assist the bystander in starting CPR in a very short time.102 6 
In making a strong recommendation despite low-certainty evidence, the task force valued the 7 
consistency of results indicating benefit for all critical and important outcomes, with the 8 
exception of shockable rhythm (no benefit). This failure to demonstrate contribution of DA-CPR 9 
to improvement in likelihood of shockable initial rhythm aligns with the adult meta-analysis.2 10 
In abstaining from recommending for or against DA-CPR when bystander CPR is already in 11 
progress, the task force noted the very-low-certainty evidence available, the consistency of 12 
inferior and neutral results for all of the critical outcomes, and the lack of any adjusted analyses 13 
for this group. The negative results associated with DA-CPR compared with unassisted 14 
bystander CPR may have several potential explanations: 1) bystander CPR was initiated earlier 15 
than DA-CPR because the bystander did not experience the delay required in calling a dispatcher 16 
and receiving instruction, or 2) the bystanders who performed CPR and refused dispatch 17 
assistance were likely trained in CPR and may have provided a higher quality of CPR than that 18 
provided by the untrained bystander who required remote dispatch assistance. This particular 19 
finding suggests the potential benefits of widespread community-based CPR training. 20 
Consideration of types of DA-CPR systems or interventions to improve the quality of DA-CPR 21 
was beyond the scope of this review. A limitation of the evidence that forms the basis of these 22 
treatment recommendations is that data are derived from only 2 countries—Japan and Korea. 23 
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The EMS systems involved may differ in their response to OHCA compared with EMS systems 1 
and responses in other regions. Thus, caution is required when attempting to extrapolate these 2 
results to different EMS systems of care. 3 
Although this review did not address the content of CPR instructions, we elected to specify that 4 
CPR instructions should include rescue breaths for pediatric cardiac arrest patients to be 5 
consistent with previous CoSTRs103 and draw attention to this important distinction from adult 6 
CPR instructions. 7 
[h3]Knowledge Gaps  8 
The Pediatric Life Support Task Force identified several knowledge gaps requiring further 9 
investigation. The overall challenge is the need to determine if dispatchers can effectively guide 10 
untrained bystanders to provide effective conventional CPR for a child in cardiac arrest. To 11 
ensure that consistent analysis is included in all future studies of DA-CPR in children, we 12 
recommend research include/address the following: 13 
 Optimal dispatcher training (and retraining) in recognizing OHCA and in providing DA-14 
CPR for children 15 
 Identification of the specific scripted language used by dispatchers and its effects on the 16 
initiation of bystander CPR 17 
 Indication of how CPR instructions are provided (by the phrasing and enunciation of 18 
words, video adjuncts via cellphone, etc) 19 
 Report of the certainty of bystander CPR (including the time required for identification of 20 
cardiac arrest, time to initiation of CPR, and whether conventional CPR or chest 21 
compression–only CPR was given)  22 
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 Inclusion of subsequent in-hospital (postarrest) factors 1 
 Indication of specific dispatcher guidance provided (eg, to pace the compression rate) 2 
when bystander CPR is already initiated 3 
 EMS response times 4 
 Analysis of cost-effectiveness of DA-CPR 5 
 Content of CPR/DA-CPR instructions, specifically addressing the role of ventilation in 6 
infant and child CPR 7 
 Report of long-term outcomes, including QoL outcomes 8 
 Adjusting for variables such as bystander CPR characteristics, patient, age, sex, and 9 
previous bystander CPR training 10 
[h2]Advanced Airway Interventions in Pediatric Cardiac Arrest 11 
The management of the airway is central in pediatric resuscitation, particularly because 12 
respiratory conditions are a frequent cause of pediatric cardiac arrest. Placement of an advanced 13 
airway device, such as a supraglottic airway (SGA) or tracheal intubation (TI), may allow more 14 
effective resuscitation than the alternative of BMV. However, uncertainties remain about the 15 
relative risk and benefit of each method of managing the airway during CPR. Persistent 16 
challenges surround issues of provision of effective (but not excessive) ventilation; delivery of 17 
continuous chest compressions; and risk of failed intubation attempts, unrecognized esophageal 18 
intubation, prolonged interruptions in chest compressions, and inadvertent excessive ventilation; 19 
these issues can all affect the quality of resuscitation.  20 
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ILCOR commissioned an SR to identify and analyze all published evidence reporting outcomes 1 
of advanced airway placement during CPR in infants and children during OHCA and IHCA.6 2 
The Pediatric Task Force analyzed and discussed the SR as well as all of the studies identified by 3 
the SR, developed a draft CoSTR, and posted it online for public comment.104 The draft CoSTR 4 
was viewed 341 times during the 2-week comment period. The 4 posted comments endorsed the 5 
CoSTR, and all acknowledged the complexity of the issues surrounding use of an advanced 6 
airway during pediatric resuscitation and the need for adequate training in all techniques.  7 
[h3]Population, Intervention, Comparator, Outcome, Study Design, and Time Frame 8 
Population: Infants and children in any setting (in-hospital or out-of-hospital) who have received 9 
chest compressions or a defibrillation dose on whom CPR is being performed  10 
Intervention: Placement of an advanced airway device  11 
Comparators: Primary—BMV alone or with non-advanced airway interventions; secondary—12 
another advanced airway device  13 
Outcomes: Any clinical outcome  14 
Study Designs: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled 15 
before-and-after studies, cohort studies) of pediatric patients eligible for inclusion; if insufficient 16 
studies available from which to draw a conclusion, case series of 4 or more may be included; 17 
case reports, unpublished studies, and nonhuman studies excluded  18 
Time Frame: All years and all languages included (as long as there is an English abstract); 19 
unpublished studies (eg, conference abstracts, trial protocols) excluded; the last search was 20 
performed on September 24, 2018 21 
PROSPERO registration: CRD42018102430 22 
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[h3]Consensus on Science 1 
The task force reviewed the evidence of outcomes with the following comparisons: TI with 2 
BMV, SGA with BMV, and TI with SGA during pediatric cardiac arrest. Detailed information 3 
from all studies reviewed is summarized in Table 11. Summative results from 8 of the studies are 4 
included in Table 12, which excluded cohort studies with results too heterogeneous to enable 5 
meta-analysis. 6 
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Table 11. Pediatric Studies Comparing Use of Bag-Mask Ventilation With Advanced Airways During Cardiac Arrest 1 
Study 
Years 
Conducted 
Setting Location 
Number of Patients/Total Treated (Percent) With: 
 
Survival With Good Neurologic Function Survival to Hospital Discharge 
TI BMV SGA TI BMV SGA 
Clinical Trials 
Gausche 2000105 1994‒1997 OHCA United States 10/290 (3.4%) 15/301 
(5.0%) 
-- 24/290 
(8.3%) 
24/301 
(8.0%) 
-- 
Observational Studies With Propensity Matching 
Andersen 
2016106 
2000‒2014 IHCA United States 185/987 (18.7%) 211/983 
(21.4%) 
-- 411/1135 
(36.2%) 
460/1135 
(40.7%) 
-- 
Hansen 2017107 2013‒2015 OHCA United States 34/727 (4.7%) 89/781 
(11.4%) 
13/215 
(6.0%) 
51/727 
(7.0%) 
110/781 
(14.1%) 
22/215 
(10.2%) 
Ohashi-Fukuda 
2017108 
2011‒2012 OHCA Japan 0/31 (0.0%) 16/346 
(4.6%) 
12/315 
(3.8%) 
4/31 
(12.9%) 
37/346 
(11.0%) 
47/315 
(14.9%) 
Simple Observational Studies 
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Study 
Years 
Conducted 
Setting Location 
Number of Patients/Total Treated (Percent) With: 
 
Survival With Good Neurologic Function Survival to Hospital Discharge 
TI BMV SGA TI BMV SGA 
Abe 2012109 2005‒2008 OHCA Japan -- -- -- 12/185 
(6.5%) 
243/2734 
(8.9%) 
9/270 
(3.3%) 
Aijian 1989110 1984‒1987 OCHA United States -- -- -- 1/28 (3.6%) 1/14 (7.1%) -- 
Deasy 2010111 1999‒2007 OHCA Australia -- -- -- 13/154 
(7.8%) 
2/26 (7.7%) -- 
Del Castillo 
2015112 
2007‒2009 IHCA Argentina, Brazil, 
Columbia, Chile, 
Ecuador Honduras, 
Italy, Paraguay, 
Portugal, Spain  
44/71 (71.0%) 43/53 
(81.1%) 
-- -- -- -- 
Guay 2004113 1983‒1987 IHCA Canada -- -- -- 20/90 
(22.2%) 
30/55  
(54.5%) 
-- 
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Study 
Years 
Conducted 
Setting Location 
Number of Patients/Total Treated (Percent) With: 
 
Survival With Good Neurologic Function Survival to Hospital Discharge 
TI BMV SGA TI BMV SGA 
Pitetti 2002114 1995‒1999 OHCA United States -- -- -- 5/150 
(3.3%) 
0/39 (0.0%) -- 
Sirbaugh 
1999115 
1992‒1995 OHCA United States 5/229 (2.2%) 0/26 (0.0%) -- 6/229 
(2.6%) 
0/26 (0.0%) -- 
Tham 2018116 2009‒2012 OHCA Japan, Korea, 
Malaysia, Singapore, 
Taiwan, Thailand, 
United Arab 
Emirates 
3/18 (16.7%) 29/791 
(3.7%) 
3/109 
(2.8%) 
3/18 
(16.7%) 
68/791 
(8.6%) 
9/109 
(8.3%) 
Simple Observational Studies Without Raw Data (Analyzed Separately From Meta-Analysis) 
Fink 2016117 2007‒2012 OHCA United States -- -- -- aOR 0.64 (CI: 0.37‒
1.13) favoring BMV 
over AAW*  
-- 
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Study 
Years 
Conducted 
Setting Location 
Number of Patients/Total Treated (Percent) With: 
 
Survival With Good Neurologic Function Survival to Hospital Discharge 
TI BMV SGA TI BMV SGA 
Tijssen 2015118 2005‒2012 OHCA Canada, USA -- -- -- aOR 0.69 (CI: 0.43‒
1.10) favoring BMV 
over AAW† 
-- 
AAW indicates advanced airway; aOR, adjusted odds ratio; BMV, bag-mask ventilation; CI, confidence interval; IHCA, in-hospital 1 
cardiac arrest; OHCA, out-of-hospital cardiac arrest; SGA, supraglottic airway; TI, tracheal intubation.  2 
*Fink 2016117: 92% of advanced airway attempts were tracheal intubation attempts. 3 
†Tijssen 2015118: 93% of advanced airway attempts were tracheal intubation attempts. 4 
5 
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Table 12. Summative Results of Studies Used in the Pediatric Airway Systematic Review, for Each Comparison and Grouped 1 
by Outcome 2 
Outcomes 
(Importance) 
Participants (Studies), n 
Certainty of 
Evidence (GRADE) 
RR  
(95% CI) 
Absolute Risk With 
Comparator (C) 
Absolute Risk Difference 
With Intervention (I) 
Tracheal Intubation (I) Versus Bag-Mask Ventilation (C)* 
Survival, favorable 
neurologic outcome 
(critical) 
591 (1 RCT)105 Low 0.69 
(0.32‒
1.52) 
50/1000 15 fewer per 1000 (from 48 
fewer to 17 more) 
 3855  
(3 propensity-matched 
observational)106-108 
Very low ‡ 150/1000 49 fewer per 1000 (from 77 
fewer to 21 fewer) 
Survival to hospital 
discharge (critical) 
591 (1 RCT)105 Low 1.04  
(0.6‒1.79) 
80/1000 3 more per 1000 (from 41 
fewer to 47 more) 
 4155 
(3 propensity-matched 
observational)106-108 
Very low † 268/1000 53 fewer per 1000 (from 20 
fewer to 87 fewer) 
 3992  
(2 observational studies)117,118 
Very low † Fink 2016: aOR 0.64 (0.37‒1.13)117 
Tijssen 2015: aOR 0.69 (0.43‒1.1)118 
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Outcomes 
(Importance) 
Participants (Studies), n 
Certainty of 
Evidence (GRADE) 
RR  
(95% CI) 
Absolute Risk With 
Comparator (C) 
Absolute Risk Difference 
With Intervention (I) 
Survival to hospital 
admission (important) 
1508 
(1 propensity-matched 
observational)107  
Very low 0.99  
(0.83‒
1.17) 
257/1000 3 fewer per 1000 (from 47 
fewer to 41 more) 
ROSC (important) 4155 
(3 propensity-matched 
observational)106-108 
Very low † 417/1000 12 more per 1000 (from 15 
fewer to 39 more) 
Supraglottic Airway (I) versus Bag-Mask Ventilation (C)* 
Survival, favorable 
neurologic outcome 
(critical) 
1657 
(2 propensity-matched 
observational)107,108 
Very low ‡ 93/1000 29 fewer per 1000 (from 75 
fewer to 17 more) 
 900 
(1 non-adjusted observational 
study)116 
Very low 0.75  
(0.23‒
2.42) 
37/1000 9 fewer per 1000 (from 43 
fewer to 24 more) 
Survival to hospital 
discharge (critical) 
3904  
(2 observational studies)109,116 
Very low ‡ 88/1000 35 fewer per 1000 (from 88 
fewer to 18 more) 
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Outcomes 
(Importance) 
Participants (Studies), n 
Certainty of 
Evidence (GRADE) 
RR  
(95% CI) 
Absolute Risk With 
Comparator (C) 
Absolute Risk Difference 
With Intervention (I) 
Survival to hospital 
admission (important) 
996 
(1 propensity-matched 
observational)107 
Very low 1.25  
(0.99‒
1.57) 
257/1000 64 more per 1000 (from 6 
fewer to 133 more) 
 900 
(1 observational study)116 
Very low 0.85 
(0.44‒
1.87) 
97/1000 15 fewer per 1000 (from 70 
fewer to 41 more) 
ROSC (important) 900 
(1 observational study)116 
Very low 1.26  
(0.82‒
1.92) 
171/1000 40 more per 1000 (from 41 
fewer to 121 more) 
Tracheal Intubation (I) versus Supraglottic Airway (C)* 
Survival, favorable 
neurologic outcome 
(critical) 
1288 
(2 propensity-matched 
observational)107,108 
Very low ‡ 47/1000 22 fewer per 1000 (from 51 
fewer to 6 more) 
 127 
(1 nonadjusted observational 
study)116 
Very low 6.06  
(1.32‒
27.7) 
28/1000 139 more per 1000 (from 36 
fewer to 314 more) 
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Outcomes 
(Importance) 
Participants (Studies), n 
Certainty of 
Evidence (GRADE) 
RR  
(95% CI) 
Absolute Risk With 
Comparator (C) 
Absolute Risk Difference 
With Intervention (I) 
Survival to hospital 
discharge (critical) 
1288 
(2 propensity-matched 
observational)107,108 
Very low ‡ 130/1000 31 fewer per 1000 (from 73 
fewer to 11 more) 
 582 
(2 observational studies)109,116 
Very low ‡ 47/1000 34 more per 1000 (from 6 
fewer to 75 more) 
Survival to hospital 
admission (important) 
942 
(1 propensity-matched 
observational)107 
Very low 0.79  
(0.63‒1.0) 
321/1000 67 fewer per 1000 (from 136 
fewer to 4 more) 
 127 
(1 observational study)116 
Very low 4.33  
(2.28‒8.2) 
128/1000 472 more per 1000 (from 
198 more to 665 more) 
ROSC (important) 1288 
(2 propensity-matched 
observational)107,108 
Very low ‡ 162/1000 26 fewer per 1000 (from 129 
fewer to 78 more) 
 127 
(1 observational study)116 
Very low 3.42 (2.16‒
5.44) 
211/1000 511 more per 1000 (from 
291 more to 732 more) 
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aOR indicates adjusted odds ratio; C, comparator; CI, confidence interval; GRADE, Grading of Recommendations, Assessment, 1 
Development, and Evaluation; I, intervention; RCT, randomized controlled trial; ROSC, return of spontaneous circulation; RR, 2 
relative risk. 3 
Summative results of studies used in the systematic review, for each comparison and grouped by outcome.  4 
*Cohort studies, amenable to meta-analysis, were not reported in this table if they produced too heterogeneous results (I2 index >75%). 5 
Studies included in this table were therefore 1 clinical trial,105 3 propensity-matched observational studies,106-108 and 4 nonadjusted 6 
observational studies.109,116-118 7 
†The first 2 studies117,118 provided retrospective cohort data in adjusted form only (aOR), not amenable to meta-analysis.  8 
‡To minimize ambiguity, RR calculations were only reported for single studies and not for meta-analysis. RR calculations were 9 
considered less informative and sometimes produced divergent results, likely a consequence of zero-numerator cells.119 10 
 11 
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[h4]Studies Comparing Tracheal Intubation With Bag-Mask Ventilation Alone 1 
Fourteen studies were included in the SR comparing TI with BMV, including 1 clinical trial105 2 
and 13 observational studies.106-118 3 
Although the clinical trial was excellent in design and execution, it was downgraded to low 4 
certainty as a result of indirectness; the study was conducted in 1994 to 1996, before more recent 5 
revisions in resuscitation guidelines that emphasize minimally interrupted chest compressions as 6 
part of high-quality CPR. This study assigned 591 children with OHCA to TI or BMV on an 7 
odd- and even-day basis. The use of TI resulted in no difference in likelihood of survival with the 8 
critical outcome of favorable neurologic function or survival to hospital discharge.105 9 
The 13 identified observational studies provided evidence of very-low or low certainty. Three of 10 
these observational studies106-108 used propensity matching to attempt to control for factors 11 
driving the decision to intubate. However, a limitation of all 3 studies was the failure to 12 
distinguish patients with unsuccessful attempts at advanced airway placement from those who 13 
were managed with BMV alone. When combined, these studies found a reduced likelihood of 14 
survival with favorable neurologic function or survival to hospital discharge associated with 15 
TI.106-108 The other 10 observational studies found no statistically significant association between 16 
TI and these outcomes.109-116,118,120 17 
[h4]Studies Comparing SupraGlottic Airway With Bag-Mask Ventilation Alone 18 
The 4 observational studies comparing SGA with BMV provided very-low certainty evidence. 19 
Two studies used propensity matching to reduce bias, but both had the limitation of failure to 20 
distinguish between patients who had unsuccessful attempts at SGA insertion and those who 21 
were managed with BMV without attempted SGA insertion.107,108 Two other observational 22 
Soar 85 
© 2019 American Heart Association, Inc. 
studies reported only nonadjusted data.109,116 None of these studies found a significant 1 
association between SGA use and survival with favorable neurologic function or survival to 2 
hospital discharge.  3 
[h4]Studies Comparing Tracheal Intubation with SupraGlottic Airway 4 
The evidence comparing TI with SGA during pediatric resuscitation comes from 4 observational 5 
studies of OHCA;107-109,116 2 of these employed propensity matching.107,108 When combined, 6 
neither the propensity-matched studies107,108 nor the nonadjusted cohort studies109,116 found a 7 
significant association between the choice of advanced airway and survival with favorable 8 
neurologic function or survival to hospital discharge. 9 
[h3]Treatment Recommendations 10 
We suggest the use of BMV rather than TI or SGA in the management of children during cardiac 11 
arrest in the out-of-hospital setting (weak recommendation, very-low-certainty evidence).  12 
There is insufficient evidence to support any recommendation about the use of TI or SGA in the 13 
management of children with cardiac arrest in the in-hospital setting.  14 
[h3]Justification and Evidence to Decision Framework Highlights 15 
Advanced airway interventions have been long-established components of the advanced life 16 
support bundle of care in adults and children. As a result of inherent limitations in their design 17 
and data sources, the available studies provide only very-low-certainty evidence about whether 18 
attempting advanced airway placement during resuscitation (ie, before ROSC) improves 19 
resuscitation outcomes. The best available data shows no benefit from advanced airway 20 
interventions, and some suggested association with harm for the critical outcomes of survival 21 
with favorable neurologic outcome and survival to hospital discharge. The effects of placement 22 
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of an advanced airway are uncertain for the short-term resuscitation outcomes of survival to 1 
hospital admission and ROSC. Although these short-term outcomes do not ultimately benefit the 2 
patient, they may benefit the family. 3 
Effective BMV, TI, and insertion of an SGA are all difficult skills that require good initial 4 
training, retraining, and quality control to be performed consistently, safely, and effectively. To 5 
be effective, pediatric advanced airway programs require a moderate investment in equipment 6 
and a significant investment in training, skills maintenance, and quality control programs. 7 
The benefit or harm associated with advanced airway-based resuscitation may differ across 8 
settings. Importantly, the available data do not inform the questions of whether better outcomes 9 
might be achieved by advanced airway-based strategies by highly trained and experienced 10 
airway operators, during long distance transport, or in prolonged resuscitation situations. The 11 
analyzed data are only relevant to advanced airway interventions during CPR and do not pertain 12 
to airway management after ROSC or in other critical situations. 13 
[h3]Knowledge Gaps 14 
This evidence evaluation did not identify any clinical trials addressing airway management 15 
during cardiac arrest in the in-hospital setting, and future studies are needed to address this 16 
knowledge gap. In addition, the only randomized clinical trial undertaken in the out-of-hospital 17 
setting105 was performed before major changes in resuscitation guidelines; future studies are 18 
needed in the out-of-hospital setting. The task force identified several additional knowledge gaps 19 
requiring further investigation, including 20 
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 Prehospital, emergency department–based, and in-hospital studies of similar design, 1 
comparing TI, SGA, and BMV with planned subgroup analyses based on patient age and 2 
etiology of arrest  3 
 Studies of advanced airway use in specific contexts, such as long-distance transport and 4 
prolonged resuscitation situations in the hands of highly trained and experienced airway 5 
operators; these are subgroups about which we have no knowledge and that are likely to 6 
be important 7 
[h2]ECPR: Infants and Children  8 
ECPR has been used with increasing frequency as rescue therapy for refractory cardiac arrest. In 9 
pediatrics, ECPR is used most frequently after postoperative IHCA associated with congenital 10 
heart disease and progression of low cardiac output or arrhythmias, although there are recent 11 
reports of applications for cardiac arrest from other causes. This topic was last reviewed by the 12 
Pediatric Life Support Task Force in 2015.121  13 
ILCOR commissioned an SR to identify and analyze all published evidence reporting outcomes 14 
of ECPR in infants, children, and adults after OHCA and IHCA.5 The Pediatric Life Support 15 
Task Force analyzed and discussed the SR as well as all of the pediatric studies identified by the 16 
SR, developed a draft CoSTR, and posted it online for public comment.122 The draft document 17 
was viewed 264 times during the 2-week comment period. The task force reviewed the single 18 
posted comment, which endorsed the CoSTR.  19 
[h3]Population, Intervention, Comparator, Outcome, Study Design, and Time Frame 20 
Population: Adults (≥18 years) and children (<18 years) with cardiac arrest in any setting (out-21 
of-hospital or in-hospital) 22 
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Intervention: ECPR, including extracorporeal membrane oxygenation or cardiopulmonary 1 
bypass, during cardiac arrest 2 
Comparator: Manual CPR and/or mechanical CPR 3 
Outcomes: Clinical outcomes, including short-term survival and neurologic outcomes (eg, 4 
hospital discharge, 28 days, 30 days, and 1 month), and long-term survival and neurologic 5 
outcomes (eg, 3 months, 6 months, and 1 year)  6 
Study Design: Randomized trials, non-RCTs, and observational studies (cohort studies and case-7 
control studies) with a control group were included; animal studies, ecological studies, case 8 
series, case reports, reviews, abstracts, editorials, comments, and letters to the editor were not 9 
included.  10 
Time Frame: All years and all languages were included (as long as there was an English 11 
abstract); unpublished studies and published abstracts (eg, conference abstracts) and trial 12 
protocols were excluded; literature search conducted on December 19, 2017 and updated to May 13 
22, 2018 14 
PROSPERO registration: CRD42018085404 15 
Note: Information about outcomes of ECPR use in adults is addressed elsewhere in this article 16 
(see “Advanced Life Support, ECPR for Cardiac Arrest: Adults”). 17 
[h3]Consensus on Science 18 
[h4]In-Hospital Cardiac Arrest 19 
For the critical outcomes of favorable longer-term neurologic outcome or of longer-term 20 
survival, no pediatric studies were identified. 21 
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For the critical outcome of favorable neurologic outcome at hospital discharge, we identified 1 
very-low-certainty evidence (downgraded for very serious risk of bias) from 1 observational 2 
study; this study associated improved outcomes with ECPR when compared with conventional 3 
CPR (conditional logistic analysis adjusted odds ratio [aOR], 2.64; 95% CI, 1.91‒3.67; 4 
propensity analysis aOR, 1.78; 95% CI, 1.31‒2.41).123  5 
For the critical outcome of survival to hospital discharge, we identified very-low-certainty 6 
evidence (downgraded for very serious risk of bias and inconsistency) from 3 studies with 7 
pediatric populations. Two studies associated improved survival with ECPR when compared 8 
with conventional CPR (aOR, 2.76; 95% CI, 2.08‒3.66123; aOR, 3.80; 95% CI, 1.40‒10.32 in 9 
medical cardiac; and aOR, 2.50; 95% CI, 1.3‒4.81 in surgical cardiac patients).124  10 
[h4]Out-of-Hospital Cardiac Arrest 11 
No studies were identified that addressed this question.  12 
[h3]Treatment Recommendations 13 
We suggest ECPR may be considered as an intervention for selected infants and children (eg, 14 
cardiac populations) with IHCA refractory to conventional CPR in settings where resuscitation 15 
systems allow ECPR to be well performed and implemented (weak recommendation, very low 16 
certainty of evidence).  17 
There is insufficient evidence in pediatric OHCA to formulate a recommendation for the use of 18 
ECPR.  19 
[h3]Justification and Evidence to Decision Framework Highlights  20 
In making a weak recommendation about the use of ECPR for pediatric IHCA, we recognize that 21 
despite lack of comparative prospective studies identified in infants and children, patients with 22 
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IHCA refractory to conventional CPR have a high probability of death unless therapies such as 1 
ECPR are used. 2 
Providers should carefully consider the fact that the pediatric ECPR studies from which these 3 
recommendations are drawn consist predominantly of children with cardiac disease. This 4 
population may not adequately represent the local population where guidelines may be 5 
implemented, so regional resuscitation councils must consider how generalizable the evidence 6 
can be to their regional systems of care. 7 
The results of ECPR studies conducted in adults cannot be extrapolated to pediatric OHCA, 8 
given the difference in causes of cardiac arrest between children and adults, the techniques and 9 
equipment applied for ECPR, and the post–cardiac arrest care interventions. 10 
As noted, ECPR has been studied in very selected populations (eg, cardiac surgical or cardiac 11 
medical) and more rarely for pediatric cardiac arrest in general (ie, across all diseases and in all 12 
hospital settings).123 In addition, it has been used in organizations with strong institutional-based 13 
commitment to sustaining a resuscitation system that includes ECPR with appropriate quality 14 
improvement systems.125,126 Such improvement systems include ongoing internal audits and 15 
iterative evaluation of performance and outcomes.125-129 As a result, these findings may not be 16 
broadly generalizable to other organizations.  17 
ECPR is a complex resuscitation intervention that requires long-term commitment to sustain the 18 
expertise, resources, training, and systems to provide support for patients and their families. 19 
Delivering this complex intervention involves added up-front investment and costs.130,131 20 
The healthcare resources necessary to provide high-quality pediatric ECPR are likely to limit its 21 
broad adoption.  22 
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[h3]Knowledge Gaps 1 
There are no published randomized trials comparing outcomes of ECPR versus conventional 2 
CPR in infants and children. As some high-volume organizations have adopted ECPR for 3 
selected pediatric populations, this comparison may not be perceived as having sufficient 4 
equipoise to allow randomization. As a result, alternative comparative study designs may be 5 
necessary to conduct clinical trials to study the following: 6 
 Comparison of the probability of survival between ECPR and conventional CPR in IHCA 7 
 Comparison of the likelihood of favorable neurologic and functional outcome between 8 
ECPR and conventional CPR in IHCA 9 
The timing and type of cannulation strategy for optimal transition from conventional CPR to 10 
ECPR remain to be studied to optimize neuro-cardiopulmonary resuscitation outcomes. The 11 
Pediatric Life Support Task Force identified the following unresolved issues: 12 
 Optimal timing for ECPR cannulation during conventional CPR  13 
 Conditions (eg, conditions with pulmonary blood flow obstruction) for which ECPR 14 
rather than conventional CPR should be considered earlier in the resuscitation  15 
 Type and anatomic approach for cannulation for ECPR that allows best cerebral-16 
cardiopulmonary resuscitation 17 
 Identification of other technical aspects of ECPR that enable optimal cerebral-18 
cardiopulmonary resuscitation, including ideal temperature management strategy, best 19 
circuit prime solution (reconstituted whole blood versus crystalloid), optimal fraction of 20 
device oxygenation to be delivered by the membrane lung, target oxygenation and 21 
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decarboxylation to be delivered during ECPR, and the inotrope or vasoactive medications 1 
delivered during ECPR that will optimize neurologic and cardiopulmonary outcomes 2 
The post–cardiac arrest care strategies after cannulation for ECPR remain to be studied, 3 
including how post–cardiac arrest care therapies should be adapted in the context of ongoing 4 
ECPR. 5 
There is an important gap in comparative studies of resuscitation for OHCA in special 6 
circumstances such as submersion or drowning, deep hypothermia or cold environment, 7 
respiratory arrest, or in the context of trauma. The Pediatric Life Support Task Force identified 8 
the following challenges for studies of ECPR for pediatric OHCA in special circumstances: 9 
 Identification of ideal select populations and circumstances to be considered for initial 10 
studies of ECPR for OHCA: Should these include children with cold-water drowning or 11 
avalanche victims or cold exposure victims?  12 
 Optimal timing for initiation of ECPR: Should it be initiated at the scene of the arrest (ie, 13 
cannulation in the field) or immediately upon arrival at the hospital?  14 
There are no published comparative studies on longer term functional outcomes or QoL 15 
outcomes in pediatric patients and in their families and/or caregivers after ECPR. The Pediatric 16 
Life Support Task Force identified the following issues to be addressed:  17 
 How longer-term functional and QoL outcomes compare between ECPR and 18 
conventional CPR for the pediatric population and their families and caregivers 19 
 How bereavement outcomes compare between families and caregivers of nonsurvivors of 20 
cardiac arrest with ECPR compared with outcomes of families and caregivers of 21 
nonsurvivors of conventional CPR 22 
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Whereas the cost-effectiveness of ECMO has been addressed in pediatric and adult publications, 1 
the cost-effectiveness of ECPR versus conventional CPR in pediatric cardiac arrest populations 2 
is not known and should be studied. 3 
[h2]Targeted Temperature Management (TTM) After Cardiac Arrest 4 
The last ILCOR Pediatric Life Support CoSTR review of pediatric TTM was published in 5 
2015.121 Since that review, additional studies of pediatric TTM have been published, particularly 6 
in the in-hospital target population. ILCOR commissioned an SR to identify and analyze all 7 
published evidence reporting outcomes of TTM in children who achieved ROSC after OHCA 8 
and IHCA.7 The Pediatric Life Support Task Force analyzed and discussed the SR as well as all 9 
of the studies identified by that review, developed a draft CoSTR, and posted it online for public 10 
comment.132 In response to the 2 posted comments, the task force included additional 11 
information in the section “Justification and Evidence to Decision Framework Highlights.”  12 
[h3]Population, Intervention, Comparator, Outcome, Study Design, and Time Frame 13 
Population: Pediatric patients (>24 hours to 18 years of age) who achieved ROSC after OHCA or 14 
IHCA  15 
Intervention: TTM with a target temperature of 32°C to 36°C  16 
Comparators: No TTM or TTM at an alternative target temperature range  17 
Outcomes:  18 
 Critical: favorable neurologic outcome (good behavioral survival) at 1 year such as 19 
Pediatric Cerebral Performance Category 1 or 2, and Vineland Adaptive Behavior Scales 20 
II 21 
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 Important: favorable neurologic outcome (at other time intervals), overall survival, and 1 
health-related QoL (HRQoL) at 3 time intervals: long-term (1‒3 years), intermediate-term 2 
(3‒6 months), and short-term (28‒30 days or hospital discharge)  3 
– HRQoL was defined using pediatric-specific QoL tools (eg, the Pediatric QoL 4 
Inventory,133 the Infant Toddler QoL Questionnaire,134 or equivalent). Potential in-5 
hospital adverse outcomes were also captured, including infection (culture proven), 6 
recurrent cardiac arrest, serious bleeding (red blood cell transfusion), and any 7 
arrhythmias (not leading to cardiac arrest).  8 
Study Designs: RCTs, quasi-randomized controlled trials (qRCTs), and nonrandomized cohort 9 
studies eligible to be included; excluded: animal studies, unpublished studies and published 10 
abstracts (eg, conference abstracts), case series  11 
Time Frame: All years to December 13, 2018  12 
Languages: All languages included (if English abstract was available) 13 
A priori Subgroups to Be Examined: Location of cardiac arrest (in-hospital and out-of-hospital), 14 
age groups, presumed etiology of cardiac arrest (cardiac, asphyxial, other), and use of 15 
extracorporeal membrane oxygenation (ECMO) 16 
PROSPERO registration: CRD42018108441 17 
[h3]Consensus on Science  18 
The review identified 2 RCTs135,136 with moderate clinical heterogeneity (different settings), low 19 
methodological heterogeneity (same methods and in-hospital management), and low or moderate 20 
statistical heterogeneity, allowing pooling of the results in the meta-analyses and separate 21 
subgroup analyses. The 2 RCTs were downgraded to low certainty of effect as the result of 22 
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inconsistency and imprecision. Because there were only 2 relatively small RCTs available, 1 
observational comparative data were considered, but we did not combine the RCT and non-RCT 2 
data. The observational studies that reported adequately adjusted results were pooled, whereas 3 
nonadjusted results are shown, where relevant, without pooling (Table 13). 4 
Soar 96 
© 2019 American Heart Association, Inc. 
Table 13. Pediatric Targeted Temperature Management in Children With Out-of-Hospital Cardiac Arrest Who Are Comatose 1 
After Return of Spontaneous Circulation: Summary of Studies and Findings 2 
Authors 
(Year) 
Study Type; 
Years 
Enrolled 
N 
Enrollment 
Criteria 
GCS/ 
Neuro 
Target 
Temperature 
Intervention 
Temperature 
Comparison 
Control 
TTM 
Duration 
Outcomes Comments 
Chang 
(2016)137 
Retrospective 
review of 
national 
OHCA 
database 
Nonrandomize
d 
1/1/2008‒ 
12/31/2014  
663 total 
TTM 81 
 
Stratified by 
shockable 
versus 
nonshockabl
e presenting 
rhythm 
OHCA surviving 
to hospital 
admission 
(excluding 
deaths in ED, 
alert status after 
ED resuscitation, 
or unknown 
neurological 
status at 
discharge) 
Not 
specified 
32°C‒34°C 
 
Based on 
intention to 
treat regardless 
of achieved 
temp or 
duration 
 
Actual 
temperature 
measures not 
included 
No standard 
care protocol 
 
Temperature 
measures not 
included 
Minimum 
12 h 
No difference in 
either survival to 
hospital discharge 
between TTM 
(48.1%) and control 
(40.2%) 
 
No difference in 
“good neurological 
recovery” (CPC 1 or 
2 at discharge) 
between TTM 
Very low 
certainty 
resulting from 
lack of 
temperature 
data and 
nonrandomize
d treatment 
allocation 
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Authors 
(Year) 
Study Type; 
Years 
Enrolled 
N 
Enrollment 
Criteria 
GCS/ 
Neuro 
Target 
Temperature 
Intervention 
Temperature 
Comparison 
Control 
TTM 
Duration 
Outcomes Comments 
 
No standard 
care protocol 
(22.2%) and control 
(18.7%) 
 
No difference in 
effect of TTM 
between shockable 
and nonshockable 
presenting rhythm 
groups 
Cheng 
(2018)138 
Retrospective 
Historic and 
concurrent 
Controls 
2013‒2015; 
Included 
81 events in 
75 pts; IHCA 
CHD* + 
CPR >5 min  
or ECPR* 
(excluded 
intracranial 
hemorrhage) 
Not 
specified 
Mean=33.6°C 
(0.2) 
0 had fever 
4/30 had  
T<32°C; 
Mean=34.7°C 
(0.8) 
2/51 had fever; 
12/51 had 
T<32°C; TTM 
<1=72 h 
≥1=48 h 
14/30 
TTM pts 
rewarmed 
early 
Survival  
Control 59.1%  
TTM 61.5% 
No significant 
difference in survival 
or LOS,  
Control group 
included more 
patients with 
single 
ventricles and 
had low mean 
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Authors 
(Year) 
Study Type; 
Years 
Enrolled 
N 
Enrollment 
Criteria 
GCS/ 
Neuro 
Target 
Temperature 
Intervention 
Temperature 
Comparison 
Control 
TTM 
Duration 
Outcomes Comments 
neonates (23‒
33%) 
TTM reached in 
1.4 h 
reached in 1.4 
h 
Follow up to 26.5 
months; fewer TTM 
patients had seizures 
(sig) 
temperature 
with nearly 
half T<32°C 
Fink  
(2010)120 
Retrospective 
cohort 
TTM patients 
after 2002  
181 total 
40 TTM  
 
OHCA and 
IHCA 
Admission to 
ICU with ROSC 
after cardiac 
arrest (even 
brief). “who 
remained 
comatose after 
ROSC” 
(excluded CHD, 
respiratory arrest 
no ROSC, brain 
Consisten
t with 
AHA 
“comatos
e”; 
specific 
neurologi
cal 
criteria 
not 
reported 
33.5°C‒34.8°C, 
mean 34.1°C 
±0.8°C 
Reached in 2.7 
±4.5 h 
(mean 0‒4); 
18% had fever, 
15% had 
T<32°C 
(associated with 
higher mortality 
“standard” 
33.6°C‒
36.3°C, 
Mean 31.6 
±19.5 h; 
38% had fever 
in first 4 days 
24 h 
(range 16‒
48 h); 60% 
of TTM 
patients 
presented 
at or 
below 
target 
temperatur
e, so some 
55% survival with no 
difference between 
TTM and control; 
<36°C or >38°C on 
admission had 
significantly higher 
mortality than 
T36°C‒38°C;  
T<32°C in 15% and 
associated w/higher 
mortality;  
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Authors 
(Year) 
Study Type; 
Years 
Enrolled 
N 
Enrollment 
Criteria 
GCS/ 
Neuro 
Target 
Temperature 
Intervention 
Temperature 
Comparison 
Control 
TTM 
Duration 
Outcomes Comments 
death prior to 
arrest) 
were 
warmed to 
target 
temperatur
e) 
 
No difference in 
hospital mortality, 
LOS 
Lin  
(2013)139 
Retrospective 
chart review 
1/1/2010‒
6/30/2012 
43 total 
15 TTM 
Both OHCA 
and IHCA 
At least 3 min 
compression; 
only those 
surviving 12 h 
included; CHD 
excluded 
TTM 
GCS 
mean 
4.67 
±1.94;  
 
Control 
GCS  
5 ±2.35 
33.5°C ±0.5°C 39% needed 
active 
rewarming to 
normothermia 
24‒72 h 57% overall survival; 
higher (78.6%) in 
TTM group versus 
46.4% in control 
group (sig) 
Some internal 
inconsistencie
s in numbers 
throughout 
manuscript 
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Authors 
(Year) 
Study Type; 
Years 
Enrolled 
N 
Enrollment 
Criteria 
GCS/ 
Neuro 
Target 
Temperature 
Intervention 
Temperature 
Comparison 
Control 
TTM 
Duration 
Outcomes Comments 
Lin 
(2018)140 
Retrospective 
cohort 2010‒
2017 
64 total 
25 TTM, all 
asphyxial 
OHCA 
CPR at least 3 
min and survival 
at least 12 h; 
excluded 45 
children, 
including 10 who 
died within 12 h, 
10 not in coma 
after ROSC, 8 
with preexisting 
neuro disease 
and 8 with TBI 
GCS ≤8 
 
TTM 
GCS  
3.4 ± 1.04  
 
Control 
GCS 
3.2 ± 0.76 
33°C within 6 h 
of arrest 
35.5°C‒
37.5°C;  
 
56.4% needed 
active warming  
 
12.8% needed 
treatment for 
T>37.5°C  
72 h Overall 1-month 
survival 42.2% 
1-month survival sig 
higher in TTM (60%) 
versus control 
(30.8%);  
 
TTM had 
significantly better 
neuro outcomes; 
TTM group had 
longer LOS 
 
Moler 
(2016)136 
International, 
multi-
institutional 
74 with 
OHCA 
drowning ≥2 
48 h to <18 years 
of age; excluded 
if GCS motor 
GCS 
motor 3 
or 4, 
33°C (32°C‒
34°C) 
36.8°C (36°C‒
37.5°C) 
120 h No difference in 28-d 
mortality or 12-mo 
survival with 
CPR duration 
longer in TTM 
36°C‒37.5°C 
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Authors 
(Year) 
Study Type; 
Years 
Enrolled 
N 
Enrollment 
Criteria 
GCS/ 
Neuro 
Target 
Temperature 
Intervention 
Temperature 
Comparison 
Control 
TTM 
Duration 
Outcomes Comments 
prospective 
RCT 
(9/1/2009‒
12/31/2012) 
mins CC*, 
remained 
comatose 
(GCS motor 
3 or 4) and 
ventilator-
dependent 
after ROSC 
 
46 
randomized 
to TTM 
group 
score 5 or 6, 
major trauma, 
inability to 
randomize within 
6 h, decision to 
withhold 
aggressive 
treatment 
comatose 
and vent 
depended 
after 
ROSC 
favorable neuro 
outcome or other 
secondary outcomes; 
culture-proven 
bacterial infection 
more common in 
TTM group; the 25 
12-mo survivors who 
received >30 min CC 
had poor functional 
outcomes (PCPC≥4) 
group and 
fewer had 
bystander 
CPR; blinding 
of caregivers 
impossible 
Moler 
(2015)136 
International, 
multi-
295 
randomized; 
48 h to <18 years 
of age; excluded 
GCS 
motor 3 
33°C (32°C‒
34°C) 
36.8°C (36°C‒
37.5°C) 
120 h No difference in 28-d 
mortality (57% in 
Witnessed 
arrest 39%, 
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Authors 
(Year) 
Study Type; 
Years 
Enrolled 
N 
Enrollment 
Criteria 
GCS/ 
Neuro 
Target 
Temperature 
Intervention 
Temperature 
Comparison 
Control 
TTM 
Duration 
Outcomes Comments 
institutional 
prospective 
RCT (9/1/2009 
to 12/31/2012) 
260 subjects 
with data—
all OHCA 
who required 
≥2 mins CC, 
remained 
comatose 
and 
ventilator-
dependent 
 
155 assigned 
to TTM  
if GCS motor 
score 5 or 6, 
major trauma, 
inability to 
randomize within 
6 h, decision to 
withhold 
aggressive 
treatment 
or 4, 
comatose 
and 
ventilator 
dependen
t after 
ROSC 
TTM, 67% in control 
group, P=0.08), 12-
mo survival (38% in 
TTM versus 29% in 
Control) or in 12-mo 
survival with 
favorable neuro 
outcome or other 
secondary outcomes; 
no difference in 
complications (eg, 
bleeding, 
arrhythmias, 
infections), although 
hypokalemia and 
and 66% of 
these received 
bystander 
CPR 
 
72% of 
patients had 
respiratory 
cause of 
arrest; 
blinding of 
caregivers was 
impossible 
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Authors 
(Year) 
Study Type; 
Years 
Enrolled 
N 
Enrollment 
Criteria 
GCS/ 
Neuro 
Target 
Temperature 
Intervention 
Temperature 
Comparison 
Control 
TTM 
Duration 
Outcomes Comments 
thrombocytopenia 
occurred more 
frequently in TTM 
group and renal 
replacement 
treatment used more 
often in control 
group; there was a 
significant difference 
in survival time with 
TTM group although 
this was secondary 
outcome 
Moler 
(2017)135 
International, 
multi-
329 patients 
randomized; 
48 h to <18 years 
of age; excluded 
GCS 
motor 3 
33°C (32°C‒
34°C) 
36.8°C (36°C‒
37.5°C) 
120 h Survival at 28 d and 
survival with ≥70 at 1 
65% had 
either cardiac 
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Authors 
(Year) 
Study Type; 
Years 
Enrolled 
N 
Enrollment 
Criteria 
GCS/ 
Neuro 
Target 
Temperature 
Intervention 
Temperature 
Comparison 
Control 
TTM 
Duration 
Outcomes Comments 
institutional 
prospective 
RCT 
(9/1/2009‒
2/27/2015; 
stopped for 
futility) 
166 to 
control 
(IHCA) 
if GCS motor 
score 5 or 6, 
major trauma, 
inability to 
randomize within 
6 h, decision to 
withhold 
aggressive 
treatment 
or 4, 
comatose 
and 
ventilator 
dependen
t after 
ROSC 
y 36% TTM versus 
39% control—no 
difference; no 
difference in 
secondary outcomes 
including alive at 1 y 
or change in VABS-
II score from 
baseline; no 
difference in 
infection, blood-
product use, serious 
arrhythmias within 7 
d 
cause of arrest 
or CHD; 
blinding of 
caregivers was 
impossible 
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Authors 
(Year) 
Study Type; 
Years 
Enrolled 
N 
Enrollment 
Criteria 
GCS/ 
Neuro 
Target 
Temperature 
Intervention 
Temperature 
Comparison 
Control 
TTM 
Duration 
Outcomes Comments 
Scholefield 
(2015)141 
Retrospective 
cohort enrolled 
January 2004 
to December 
2010 following 
OHCA 
73 patients; 
38 
randomized 
to TTM 
1 day; 16 years, 
admitted after 
OHCA with 
ROSC 
Not stated 
although 
cited the 
ILCOR 
guidance 
for TTM 
for 
patients 
who 
remain 
comatose 
after 
ROSC 
from 
32°C‒34°C; 4 
 patients (11%) 
experienced 
“overshoot” 
cooling to 
<32°C and all 
11 died; only 
3% (1 patient) 
developed 
temperature 
>38°C 
Called 
“standard 
temperature 
management or 
STM)” with 
rescue 
temperature 
controlling 
measures to 
keep 
temperature  
≤38°C; 
38% had fever 
>38°C 
22.5 h Overall survival was 
29% and was not 
significantly different 
between TTM (34%) 
versus control (23%); 
the study was 
underpowered to 
detect significant 
difference in hospital 
survival; TTM group 
had more bradycardia 
and hypotension and 
had longer LOS 
Significantly 
more patients 
in TTM group 
(81% versus 
47%) had 
bystander 
CPR; TTM 
used more 
often in 
patients with 
unknown 
cause of arrest 
and higher 
predicted 
mortality and 
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Authors 
(Year) 
Study Type; 
Years 
Enrolled 
N 
Enrollment 
Criteria 
GCS/ 
Neuro 
Target 
Temperature 
Intervention 
Temperature 
Comparison 
Control 
TTM 
Duration 
Outcomes Comments 
cardiac 
arrest 
used less in 
those with 
traumatic 
arrest 
(including 
TBI), so 
control group 
had more 
patients with 
traumatic 
arrest; study 
enrollment 
bridged a 
period of 
major change 
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Authors 
(Year) 
Study Type; 
Years 
Enrolled 
N 
Enrollment 
Criteria 
GCS/ 
Neuro 
Target 
Temperature 
Intervention 
Temperature 
Comparison 
Control 
TTM 
Duration 
Outcomes Comments 
in basic life 
support 
guidelines 
Torres-
Andres 
(2018)142 
Retrospective 
observational 
study of all 
witnessed 
OHCA and 
IHCA between 
May 2007 and 
July 2015 
treated with 
ECPR 
58 
consecutive 
patients 
receiving 
ECPR; 28 
also treated 
with TTM 
Witnessed IHCA 
(only 3 of 58 
patients) or 
OHCA; receipt 
of advanced 
CPR, no ROSC 
within 15 min of 
CPR; no 
contraindication 
to mechanical 
circulatory 
support; 
Not stated 34°C‒35°C Controlled 
normothermia 
avoiding body 
temperature 
>37°C 
 Overall survival to 
hospital discharge: 
65.5%, and 3-y 
survival is 62.1%; 
survival to hospital 
discharge 
significantly higher 
among those treated 
with TTM (75%) 
versus control (55%) 
with good quality of 
life inventory and 
Nonsurvivors 
more likely to 
have >1 ECPR 
event 
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Authors 
(Year) 
Study Type; 
Years 
Enrolled 
N 
Enrollment 
Criteria 
GCS/ 
Neuro 
Target 
Temperature 
Intervention 
Temperature 
Comparison 
Control 
TTM 
Duration 
Outcomes Comments 
hypothermia was 
at discretion of 
care team 
family functioning; 
50% of survivors had 
evidence of 
intracranial injuries 
(versus 58.3% of 
nonsurvivors) 
CC indicates chest compressions; CHD, congenital heart disease; CPC, Cerebral Performance Category; CPR, cardiopulmonary 1 
resuscitation; ECPR, extracorporeal CPR; ED, emergency department; GCS, Glasgow Coma Scale; ICU, intensive care unit; IHCA, 2 
in-hospital cardiac arrest; ILCOR, International Liaison Committee on Resuscitation; LOS, length of stay; OHCA, out-of-hospital 3 
cardiac arrest; PCPC, Pediatric Cerebral Performance Category ; RCT, randomized controlled trial; ROSC, return of spontaneous 4 
circulation; STM, standard temperature management; TBI, traumatic brain injury; TTM, targeted temperature management; VABS-II, 5 
Vineland Adaptive Behavior Scales II. 6 
 7 
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[h4]Favorable Neurobehavioral Survival  1 
For the primary outcome of long-term favorable neurologic outcome (1 year), a pooled analysis 2 
of the 2 RCTs (low certainty of evidence) found no statistically significant benefit of TTM at 3 
32°C to 34°C compared with TTM at 36°C to 37.5°C.135,136 Two adjusted cohort studies reported 4 
no statistically significant benefit in either intermediate-term143 or short-term favorable 5 
neurologic outcome associated with use of TTM 32°C to 34°C compared with TTM at 36°C to 6 
37.5°C.137  7 
[h4]Survival  8 
For the secondary outcome of overall survival, a pooled analysis of the 2 RCTs (very-low 9 
certainty of effect, downgraded for inconsistency and imprecision) found no statistically 10 
significant benefit in either long-term or short-term survival of TTM at 32°C to 34°C compared 11 
with TTM at 36°C to 37.5°C.135,136 One retrospective cohort study found no benefit in adjusted 12 
intermediate-term survival associated with TTM at 32°C to 34°C versus TTM at 36°C to 13 
37.5°C.143 Three cohort studies also reported no associated increase in adjusted short-term 14 
survival associated with use of TTM 32°C to 34°C compared with TTM at 36°C to 15 
37.5°C.120,137,143   16 
[h4]Adverse Outcomes: Infection  17 
A pooled analysis of the 2 RCTs found no statistical difference in culture-proven infection from 18 
TTM at 32°C to 34°C compared with TTM at 36°C to 37.5°C.135,136 Four cohort studies reported 19 
on infection; unadjusted outcomes were not pooled, but none of the studies showed a statistically 20 
significant difference in infection with use of TTM 32°C to 34°C compared with TTM at 36°C to 21 
37.5°C.120,138,140,143  22 
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[h4]Adverse Outcomes: Recurrent Cardiac Arrest  1 
Pooled analysis of the 2 RCTs found no difference in rate of recurrent cardiac arrest from TTM 2 
at 32°C to 34°C compared with TTM at 36°C to 37.5°C.135,136 Two cohort studies reported 3 
unadjusted recurrent cardiac arrest rates that could not be pooled; none of the individual studies 4 
showed statistically significant association of increased recurrent arrest with use of TTM 32°C to 5 
34°C compared with TTM at 36°C to 37.5°C.120,143 6 
[h4]Adverse Outcomes: Serious Bleeding  7 
Pooled analysis of the 2 RCTs found significant increase in serious bleeding from TTM at 32°C 8 
to 34°C compared with TTM at 36°C to 37.5°C.135,136 Two observational cohort studies reported 9 
unadjusted ORs for serious bleeding; none of the individual studies showed association of 10 
statistically significant increase in bleeding with use of TTM 32°C to 34°C compared with TTM 11 
at 36°C to 37.5°C .120,143 12 
[h4]Adverse Outcomes: Arrhythmias  13 
Pooled analysis of the 2 RCTs found no statistical increase in arrhythmias from TTM at 32°C to 14 
34°C compared with TTM at 36°C to 37.5°C.135,136 Five observational studies reported 15 
unadjusted outcomes for arrhythmias; 1 reported an association of statistically significant 16 
increase in arrhythmias; the other 3 studies reported no statistically significant increase or 17 
decrease in arrhythmias associated with use of TTM 32°C to 34°C compared with TTM at 36°C 18 
to 37.5°C.120,138,140,141,143  19 
[h4]Subgroup Analysis: Location of Cardiac Arrest  20 
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For the predetermined subgroup analysis by location of arrest (OHCA or IHCA), no meta-1 
analyses could be completed because there is only 1 RCT for each subgroup and the 2 
observational studies had methodologic heterogeneity.  3 
For OHCA, the single RCT did not find statistically significant benefit of TTM 32°C to 34°C 4 
compared with TTM at 36°C to 37.5°C.136 One of the 3 cohort studies found (in unadjusted 5 
results) association of increased survival and good behavioral survival with 72 hours of TTM at 6 
32°C to 34°C compared with TTM at 36°C to 37.5°C.140 The other 2 cohort studies did not 7 
report statistically significant benefit or harm.137,141 An exploratory analysis was conducted to 8 
determine if the addition of a hypothetical OHCA RCT that yielded similar results as the 9 
Therapeutic Hypothermia After Pediatric Cardiac Arrest (THAPCA) OHCA study would change 10 
the pooled analysis confidence interval to favor TTM at 32°C to 34°C.136 Enrollment of 200 11 
patients in such a hypothetical RCT would be required to demonstrate a statistically significant 12 
benefit for favorable neurologic outcome at 1 year. 13 
The IHCA RCT did not find statistical benefit or harm of TTM at 32°C to 34°C compared with 14 
TTM at 36°C to 37.5°C.135 The point estimates for outcomes of 3 different observational cohort 15 
studies are on both sides of null effect.138,142,143 An exploratory analysis indicated that an 16 
additional hypothetical RCT of 6000 patients with similar outcome to the IHCA THAPCA 17 
RCT135 would be required to demonstrate a statistically significant harm of TTM at 32°C to 34°C 18 
in favorable neurologic outcome at 1 year compared with TTM at 36°C to 37.5°C. 19 
[h4]Subgroup Analysis: Etiology of Arrest  20 
Two retrospective observational cohort studies of cardiac arrest with presumed cardiac etiology 21 
could not be pooled but separately reported no significant benefit or harm in short-term survival 22 
associated with TTM at 32°C to 36°C compared with TTM at 36°C to 37.5°C (or no TTM).138,142  23 
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Two observational cohort studies (and a pilot publication of one of those studies) reported on the 1 
favorable neurologic outcome and survival outcomes for patients with predominantly (>80%) 2 
presumed asphyxial etiology.120,139,140  High risk of bias and lack of adjusted outcomes precluded 3 
pooling of data. One OHCA study found a statistically significant benefit for both favorable 4 
neurologic outcome and survival associated with TTM at 32°C to 36°C for 72 hours.140 All of the 5 
point estimates for outcomes favored TTM at 32°C to 36°C.  6 
The OHCA THAPCA study published a nonrandomized subgroup analysis of drowning as an 7 
etiology.144 There was no statistically significant benefit of the intervention for survival or 8 
favorable neurologic outcome. 9 
[h4]Subgroup Analysis: ECMO  10 
Although some patients in several of the studies underwent ECMO, outcome data were available 11 
from only 2 studies. The THAPCA IHCA RCT (nonrandomized co-intervention, of low-12 
certainty evidence) found no statistically significant difference in long-term favorable neurologic 13 
outcome (at 1 year) for TTM at 32°C to 34°C compared with TTM at 36°C to 37.5°C.135 In 1 14 
observational cohort study, all patients received ECMO; they reported no statistical increase in 15 
short-term survival.142 16 
[h3]Treatment Recommendations  17 
We suggest that for infants and children with OHCA, TTM be used in the post–cardiac arrest 18 
period to maintain a central temperature <37.5°C (weak recommendation, moderate-certainty 19 
evidence). Based on 2 randomized trials and 8 retrospective observational cohort studies that 20 
provided comparative data on favorable neurologic outcome, survival, and in-hospital adverse 21 
events, there is inconclusive evidence to support or refute the use of TTM to 32°C to 34°C 22 
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compared with TTM at 36°C to 37.5°C (or an alternative temperature) for children who achieve 1 
ROSC after cardiac arrest.  2 
[h3]Justification and Evidence to Decision Framework Highlights 3 
The evidence in this review is dominated by the 2 THAPCA RCTs.135,136 These studies included 4 
only children aged 2 days to 18 years who had received at least 2 minutes of CPR and who 5 
remained comatose and ventilator-dependent after ROSC. There were many patient exclusions, 6 
including use of ECMO, severe trauma, previous cardiac arrest, pre-existing life-limiting 7 
conditions, severe bleeding, and continuous epinephrine infusion. The findings of this review 8 
should be considered in context of this limitation. 9 
In making this recommendation, the task force preferred the use of TTM of 32°C to 34°C as 10 
opposed to TTM at 36°C to 37.5°C because although the THAPCA OHCA study136 did not 11 
demonstrate success for the primary outcome (favorable neurologic status at 1 year), it was 12 
underpowered to show a significant difference for survival, for which the lower 95% CI 13 
approached 1. The point estimates for survival in the 3 cohort studies of OHCA or presumed 14 
asphyxial arrest120,139,140 favored TTM 32°C to 34°C. There were insufficient data on IHCA 15 
patients, who represent a population with different pre-existing conditions and etiology of arrest.  16 
The task force noted that hyperthermia occurs frequently in the postarrest period; fever is 17 
potentially harmful and should be avoided. Finally, the provision of TTM can be resource 18 
intensive. These resources, the associated expertise necessary to deliver and maintain TTM, and 19 
the presence of appropriate systems of critical care are required to provide optimal post-ROSC 20 
care. The task force noted that the application of TTM may require sedation, analgesia, and 21 
neuromuscular blocking drugs that will modify neurologic assessment. 22 
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[h3]Knowledge Gaps 1 
This evidence evaluation did not address training, logistical, operational, or economic issues 2 
pertaining to TTM. It also did not compare other temperature ranges and did not address the 3 
duration of TTM. In addition, the task force identified several knowledge gaps requiring further 4 
investigation, including  5 
 The use of TTM 32°C to 34°C for children after OHCA 6 
 Asphyxial arrest and the use of TTM at 36°C to 37.5°C in IHCA patients 7 
[h1]Neonatal Life Support Task Force 8 
[h2]Initial Oxygen Concentration for Term Infants at Birth 9 
Administration of high oxygen concentrations leads to free radical formation and may be toxic to 10 
newly born lungs, eyes, brains, and other organs.145,146 In 2010, the ILCOR NLS Task Force 11 
CoSTR Update noted that it was best to start with 21% oxygen when term newborns received 12 
positive-pressure ventilation in the delivery room. The recommendation was based on a meta-13 
analysis that found lower mortality when room air instead of 100% oxygen was used.147 The 14 
evidence review for this question did not use GRADE methodology148 to analyze the published 15 
studies. This topic was not addressed for term infants in the 2015 CoSTR update.149 Questions 16 
remain about the risks of hypoxemia versus hyperoxemia for late preterm and term newborns 17 
who receive respiratory support in the delivery room. As a consequence, the ILCOR NLS Task 18 
Force undertook an SR with meta-analysis of the relevant available evidence using GRADE 19 
methodology148 on the topic of lower oxygen versus higher concentrations of oxygen for 20 
initiation of resuscitation of newborn infants at 35 weeks’ gestation or greater.8 21 
[h3]Population, Intervention, Comparator, Outcome, Study Design, and Time Frame 22 
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Population: Newborn infants (≥35 weeks’ gestation) who receive respiratory support at birth 1 
Intervention: Lower initial oxygen concentration (≤50% O2)  2 
Comparison: Higher initial oxygen concentration (˃50% O2) 3 
Outcomes: 4 
 Primary: All-cause short-term mortality (in-hospital or 30 days) 5 
 Secondary: All-cause long-term mortality (13 years); long-term neurodevelopmental 6 
impairment (NDI) (13 years); hypoxic-ischemic encephalopathy (Sarnat Stage 2‒3)150 7 
Study Designs: RCTs, qRCTs, and nonrandomized cohort studies included; animal studies, 8 
unpublished studies and published abstracts (eg, conference abstracts) excluded 9 
Time Frame: 1980 to August 10, 2018 10 
A priori Subgroups to Be Examined: Gestational age (≥35 weeks, ≥37 weeks); grouped lower 11 
and higher oxygen concentrations; explicit oxygen saturation targeting versus no oxygen 12 
saturation targeting 13 
PROSPERO registration: CRD42018084902 14 
[h3]Consensus on Science 15 
The SR identified 10 trials and 2 follow-up studies involving 2164 newborns, but 3 of the trials 16 
had critical risk of bias and were included in only the sensitivity analyses.8 Data from 1469 term 17 
and late preterm infants (≥35 weeks) in 7 randomized and qRCTs were included. All identified 18 
studies compared 21% (or air) with 100% oxygen concentration; no other initial oxygen 19 
concentrations were reported. No data specific to 37 weeks’ gestation or greater was found, and 20 
none of the studies used targeted oxygen saturation (SpO2) monitoring.  21 
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A draft CoSTR document based on the SR was posted for a 2-week public commenting period 1 
on January 15, 2019.151  During the comment period, the draft CoSTR was viewed 3564 times. 2 
The NLS Task Force received 47 comments that were subsequently sorted into 4 main 3 
categories: 1) agreement with the CoSTR as written; 2) responses that demonstrated a need for 4 
more explicit emphasis that the intent of the PICOST was to address initial oxygen concentration 5 
(not a static delivery concentration); 3) questions about special situations, such as oxygen use 6 
during cardiac compressions or in the unique circumstance of newborns with anomalies such as 7 
pulmonary hypoplasia or congenital diaphragmatic hernia; and 4) desire for stronger emphasis 8 
about the need for more evidence using current methods of oxygen monitoring and titration, and 9 
additional interval oxygen concentrations for infants at 35 weeks’ gestation or greater. In 10 
response to the public comments, the NLS Task Force included additional information to address 11 
questions and comments about the 3 main categories of concerns. 12 
[h4]Short-Term Mortality (In-Hospital or 30 Days) 13 
For this critical outcome, evidence of low certainty (downgraded for risk of bias and 14 
imprecision) from 7 RCTs (and qRCTs) involving 1469 newborn infants at 35 weeks’ gestation 15 
or greater receiving respiratory support at birth showed benefit of starting with 21% oxygen 16 
compared with 100% oxygen (RR, 0.73; 95% CI, 0.57‒0.94; I2=0%); 46/1000 fewer babies died 17 
when respiratory support at birth was started with 21% compared with 100% oxygen (95% CI, 18 
73/1000 fewer to 10/1000 fewer).152-158 19 
[h4]Long-Term Mortality (1‒3 Years) 20 
For this critical outcome, no evidence was identified. 21 
[h4]NDI (13 Years) 22 
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Among survivors who were assessed for this critical outcome, evidence of very-low certainty 1 
(downgraded for risk of bias and imprecision) from 2 RCTs (and qRCTs) involving 360 term and 2 
late preterm newborns (≥35 weeks) who received respiratory support at birth showed no 3 
statistically significant benefit or harm of starting with 21% compared with 100% oxygen (RR, 4 
1.41; 95% CI, 0.77‒2.60; I2=0%); 36/1000 more babies with NDI when respiratory support at 5 
birth was started with 21% compared with100% oxygen (95% CI, 20/1000 fewer to 142/1000 6 
more).156,159   7 
[h4]Hypoxic-Ischemic Encephalopathy (Sarnat Stage 2‒3)150 8 
For this critical outcome, evidence of low certainty (downgraded for risk of bias and 9 
imprecision) from 5 RCTs (and qRCTs) involving 1359 term and late preterm newborns (≥35 10 
weeks’ gestation) receiving respiratory support at delivery showed no statistically significant 11 
benefit or harm of 21% compared with 100% oxygen (RR, 0.90; 95% CI, 0.71‒1.14; I2=8%); 12 
20/1000 fewer babies with hypoxic-ischemic encephalopathy when respiratory support at birth 13 
was started with 21% compared with 100% oxygen (95% CI, 57/1000 fewer to 27/1000 14 
more).152,153,155,156,158 15 
[h4]Subgroup Infants 37 Weeks’ Gestation or Greater  16 
No data for the planned subgroup analysis for infants 37 weeks’ gestation or greater was found. 17 
[h4]Intermediate Initial Oxygen Concentrations 18 
No studies were identified that compared any intermediate initial oxygen concentrations. 19 
[h4]Oxygen Saturation Targeting Versus No Oxygen Saturation Targeting 20 
No studies were identified that used SpO2 targeting. 21 
[h3]Treatment Recommendations 22 
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For newborn infants at 35 weeks’ gestation or greater receiving respiratory support at birth, we 1 
suggest starting with 21% oxygen (air) (weak recommendation, low-certainty evidence). 2 
We recommend against starting with 100% oxygen (strong recommendation, low-certainty 3 
evidence). 4 
[h3]Justification and Evidence to Decision Framework Highlights 5 
Parents and clinicians rate mortality as a critical outcome. Despite the low certainty of the 6 
evidence, the large reduction in the primary outcome of short-term mortality (number needed to 7 
treat=22) with no demonstrated adverse effects favors use of 21% oxygen as the initial gas for 8 
resuscitation for newborns at 35 weeks’ gestation or greater. Although there are no published 9 
cost data, it is likely that initiating resuscitation with 21% oxygen does not add cost and might 10 
result in cost savings compared with use of initial 100% oxygen in some settings. Babies born in 11 
low-resource settings demonstrate increased mortality and morbidity. Therefore, it is plausible 12 
that using 21% oxygen compared with 100% oxygen has greater impact in low-resource settings. 13 
Use of 21% oxygen for initial resuscitation is universally feasible.  14 
To be clear, we emphasize that the recommendation for 21% oxygen refers to the initial 15 
concentration of oxygen at the initiation of respiratory support. It does not address the question 16 
of how to titrate the oxygen concentration as resuscitation progresses; no evidence was found to 17 
guide this aspect of oxygen delivery. Once such evidence is published, the Neonatal Task Force 18 
will initiate a systematic review to assess the effect and optimal  methods of titration of oxygen 19 
concentrations during resuscitation. We found no studies that evaluated the initial oxygen 20 
concentration for specific special circumstances such as congenital diaphragmatic hernia or 21 
pulmonary hypoplasia.  22 
[h3]Knowledge Gaps 23 
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The NLS Task Force identified the following knowledge gaps requiring further investigation, 1 
including 2 
 Studies in late preterm (35‒36 weeks’ gestation) infants: few of these infants were 3 
included in the published studies, leading to lower certainty in the evidence for this 4 
gestational age group 5 
 Research to assess the impact of titration of oxygen to oxyhemoglobin saturation (SpO2) 6 
targets as the resuscitation progresses: monitoring  SpO2 and titration of oxygen 7 
concentration was not routinely used in the studies included in the SR for this CoSTR  8 
 Comparison of initial oxygen concentrations intermediate between 21% and 100%: in the 9 
SR for this CoSTR, no studies were found that compared any oxygen concentrations 10 
other than 21% versus 100% 11 
 Determining if delayed cord clamping affects the impact of initial inspired oxygen 12 
concentration 13 
 The effect of initial oxygen concentrations on long-term NDI; studies published to this 14 
date have been of very-low certainty of evidence 15 
 The optimal initial oxygen concentrations needed in special circumstances such as 16 
newborns with pulmonary hypoplasia, congenital diaphragmatic hernia, and other 17 
anomalies 18 
[h2]Initial Oxygen Concentration for Preterm Infants at Birth  19 
Preterm newborn infants are particularly vulnerable to oxidative stress resulting from reduced 20 
antioxidant defenses and frequent exposure to oxygen during stabilization in the delivery 21 
room.160 Many common complications of prematurity are associated with oxygen toxicity, 22 
including bronchopulmonary dysplasia, retinopathy of prematurity, and intraventricular 23 
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hemorrhage. Medical practitioners who stabilize preterm infants at birth must try to prevent 1 
hypoxia while limiting excess oxygen to prevent toxic effects. In 2015, the ILCOR NLS Task 2 
Force CoSTR Update recommended starting with 21% to 30% oxygen for preterm newborns 3 
needing respiratory support in the delivery room.149 This was based on meta-analysis findings of 4 
no benefit for any important or critical outcomes when high oxygen concentrations were used. 5 
Additional studies are now available, so the ILCOR NLS Task Force undertook an SR with 6 
meta-analysis using GRADE methodology148 of the relevant available evidence about the effects 7 
of lower versus higher oxygen concentrations for initiation of resuscitation of preterm newborn 8 
infants.9 9 
[h3]Population, Intervention, Comparator, Outcome, Study Design, and Time Frame 10 
Population: Preterm newborn infants (<35 weeks’ estimated gestational age) who receive 11 
respiratory support at birth  12 
Intervention: Lower initial oxygen concentration (≤50% O2) 13 
Comparison: Higher initial oxygen concentration (>50% O2) 14 
Outcomes:  15 
 Primary: All-cause short-term mortality (in-hospital or 30 days) 16 
 Secondary: All-cause long-term mortality (1‒3 years); long-term NDI (1‒3 years); 17 
retinopathy of prematurity (stages III‒V);161 necrotizing enterocolitis stage II 18 
(pneumotosis) or III (surgical)162; bronchopulmonary dysplasia (moderate to severe)163; 19 
major intraventricular hemorrhage (grade III/IV)164; time to heart rate greater than 20 
100/min 21 
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Study Designs: RCTs, qRCTs, and nonrandomized cohort studies included; animal studies, case 1 
series, and unpublished studies and published abstracts (eg, conference abstracts) excluded  2 
Time Frame: 1980 to August 10, 2018  3 
A priori Subgroups to Be Examined: Gestational age (≤32 weeks, ≤28 weeks); grouped lower 4 
and higher initial oxygen concentrations (21% O2 compared with 100% O2, 21%‒30% compared 5 
with 80%‒100% only, 30% compared with 90%‒100%, 50% compared with 100%, 30% 6 
compared with 60%‒65%); explicit SpO2 targeting versus no SpO2 targeting  7 
PROSPERO registration: CRD42018084902 8 
[h3]Consensus on Science 9 
The SR found 16 eligible studies that included 5697 preterm newborns.9 This constituted 10 10 
RCTs, 2 follow-up studies, and 4 observational cohort studies. The majority (9/10) of the RCTs 11 
used 21% to 30% as the initial low oxygen concentration165-173  with only 1 small RCT 12 
employing 50% for the initial low oxygen group.174 All observational studies used 21% oxygen 13 
as the initial low oxygen concentration.175-178 Six of 10 RCTs used 100% oxygen,166,168-170,173,174 14 
1 RCT used 90%, 167 1 RCT used 80%,165 and 2 RCTs used greater than 60%171,172 as the high 15 
initial oxygen concentration. All observational studies used 100% as the high initial oxygen 16 
concentration. A majority of RCTs (8/10),166-173 as well as all of the observational cohort 17 
studies175-178 used SpO2 targeting as a co-intervention. All results are presented as RR with 95% 18 
CI and absolute difference with 95% CI. 19 
A draft CoSTR document based on the SR was posted for a 2-week public commenting period 20 
on January 15, 2019.179 During the comment period, the draft CoSTR was viewed 7387 times, 21 
suggesting intense interest within the global neonatal community. The NLS Task Force received 22 
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52 comments that were subsequently grouped into 3 categories: 1) those that agreed with the 1 
draft CoSTR as written; 2) those that wanted clarification on what the phrase “no benefit or 2 
harm” truly meant; and 3) those that expressed disappointment that the science does not yet 3 
provide a clearer answer. As a result of the public comments, the NLS Task Force included 4 
additional information to address these concerns. 5 
[h4]All Preterm Gestational Ages Combined (<35 Weeks’ Gestation) 6 
Overall, evidence of very-low certainty (downgraded for risk of bias and imprecision) for 7 
newborn infants at less than 35 weeks’ gestation receiving respiratory support at birth showed no 8 
statistically significant benefit or harm of lower initial oxygen concentration (≤50%) compared 9 
with higher initial oxygen concentration (>50%) about the following critical outcomes (see Table 10 
14 for data): all-cause short-term mortality (in-hospital or 30 days), all-cause long-term 11 
mortality (1‒3 years), long-term NDI (moderate-severe, 1‒3 years), retinopathy of 12 
prematurity (Grade III‒V),161 necrotizing enterocolitis (Bell’s Grade II‒III),162 13 
bronchopulmonary dysplasia (moderate to severe),163 or major intraventricular 14 
hemorrhage (Grade III‒IV).164 For the important outcome of time to heart rate greater than 15 
100/min after delivery, the limitation of the direct evidence for newborn infants at less than 35 16 
weeks’ gestation precluded meta-analysis. 17 
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Table 14. Meta-analysis of RCTs Comparing Initial Low and High Oxygen Concentration for All Preterm Gestational Ages 1 
Combined (<35 Weeks’ Gestation) 2 
Outcome 
Papers With Outcome of 
Interest 
Total 
N 
Certainty of 
Evidence 
Relative Risk ([95% CI]; I2) Absolute Difference (95% CI) 
Short-term mortality (in 
hospital or 30 days) 
Lundstrom 1995165 174 
Wang 2009166 Vento 
2009167Rabi 2011168 
Armanian 2012169 
Kapadia 2013170 Aguar 
2013171 Rook 2014172 Oei 
2017173 
968 Very low 0.83 ([95% CI, 0.50‒1.37]; 
I2=18%) 
15/1000 fewer deaths when lower 
compared with higher initial oxygen 
concentration was used (44/1000 fewer 
to 32/1000 more) 
Long-term mortality (1‒3 
years) 
Boronat 2016180 Thamrin 
2018181 
491 Very low 1.05 ([95% CI, 0.32‒3.39]; 
I2=79%) 
5/1000 more deaths when lower 
compared with higher initial oxygen 
concentration was used (71/1000 fewer 
to 248/1000 more) 
NDI (moderate-severe at 
1‒3 years) 
Boronat 2016180 Thamrin 
2018181 
389 Very low 1.14 ([95% CI, 0.78‒1.67]; 
I2=0) 
27/1000 more with NDI when lower 
compared with higher initial oxygen 
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concentration was used (42/1000 fewer 
to 129/1000 more) 
Retinopathy of 
prematurity (Grade III‒
V) 
Lundrom 1995165 Harling 
2005174 Vento 2009167 
Kapadia 2013170 Aguar 
2013171 Rook 2014172 Oei 
2017173  
806 Very low 0.73 ([95% CI, 0.42‒1.27]; 
I2=0%) 
19/1000 fewer with retinopathy of 
prematurity (Grade III‒V) when lower 
compared with higher initial oxygen 
concentration was used (42/1000 fewer 
to 19/1000 more) 
Necrotizing enterocolitis 
(Bells’s Grade II‒III) 
Lundstrom 1995165 Harling 
2005174 Wang 2008166 
Vento 2009167 Kapadia 
2013170 Aguar 2013171 
Rook 2014172 Oei 2017173 
847 Very low 1.34 ([95% CI, 0.63‒2.84]; 
I2=0%) 
12/1000 more with necrotizing 
enterocolitis when lower initial 
compared with higher initial oxygen 
concentration was used (13/1000 fewer 
to 65/1000 more) 
Bronchopulmonary 
dysplasia (moderate to 
severe) 
Harling 2005174 Wang 
2008166 Vento 2009167 
Rabi 2011168 Kapadia 
2013170 Aguar 2013171 
Rook 2014172 Oei 2017173 
843 Very low 1.00 ([95% CI, 0.71‒1.40]; 
I2=47%) 
0/1000 fewer with bronchopulmonary 
dysplasia when lower compared with 
higher initial oxygen concentration 
was used (77/1000 fewer to 107/1000 
more) 
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Major intraventricular 
hemorrhage (Grade III‒
IV) 
Lundstrom 1995165 Wang 
2009166 Vento 2009167 
Kapadia 2013170 Aguar 
2013171 Rook 2014172 Oei 
2017173  
795 Very low 0.96 ([95% CI, 0.61‒1.51]; 
I2=0%) 
3/1000 fewer with major 
intraventricular hemorrhage (Grade 
III‒IV) when lower compared with 
higher initial oxygen concentration 
was used (32/1000 fewer to 42/1000 
more) 
CI indicates confidence interval; NDI, neurodevelopmental impairment; RCT, randomized controlled trial. 1 
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[h4]Subgroup Newborn Infants 32 Weeks’ Gestation or Less 1 
For the critical outcome of all-cause short-term mortality (in-hospital or 30 days), the evidence 2 
of very-low certainty (downgraded for risk of bias and imprecision) from 8 RCTs with 837 3 
newborn infants at 32 weeks’ gestation or less receiving respiratory support at birth showed no 4 
statistically significant benefit or harm of lower initial oxygen concentration compared with 5 
higher initial oxygen concentration (RR, 0.93; 95% CI, 0.55‒1.55; I2=15%); 6/1000 fewer with 6 
short-term mortality when lower compared with higher initial oxygen concentration was used 7 
(95% CI, 39/1000 fewer to 47/1000 more).166-168,170-174 8 
[h4]Subgroup Newborn Infants 28 Weeks’ Gestation or Less 9 
For the subgroup analysis of newborn infants 28 weeks’ gestation or less receiving respiratory 10 
support at birth, evidence of very-low certainty (downgraded for risk of bias and imprecision) 11 
showed no statistically significant benefit or harm of lower initial oxygen concentration (≤50%) 12 
compared with higher initial oxygen concentration (>50%), for the following critical outcomes 13 
(see Table 15 for data): short-term mortality (in-hospital or 30 days), long-term mortality (1‒3 14 
years), long-term NDI (moderate-severe, 1‒3 years); retinopathy of prematurity (Grade III‒V),161 15 
necrotizing enterocolitis (Bell’s Grade II‒III),162 bronchopulmonary dysplasia (moderate to 16 
severe),163 major intraventricular hemorrhage (Grade III‒IV).16417 
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Table 15. Meta-analysis of RCTs Comparing Initial Low and High Oxygen Concentration for 28-Week or Less Gestational 1 
Age Subgroup  2 
Outcome 
Papers With Outcome of 
Interest 
Total N 
Certainty of 
Evidence 
Relative Risk  
([95% CI]; I2) 
Absolute Difference (95% CI) 
Short-term mortality 
(in hospital or 30 
days) 
Wang 2009166 Vento 2009167 
Rabi 2011168 Kapadia 2013170 
Aguar 2013171 Rook 2014172 
Oei 2017173 
467 Very low 0.92 ([95% CI, 0.43‒
1.94]; I2=45%) 
10/1000 fewer with short-term mortality when 
lower compared with higher initial oxygen 
concentration was used (70/1000 fewer to 
116/1000 more) 
Long-term mortality 
(1‒3 years) 
Thamrin 2018181 86 Very low 2.11 ([95% CI, 0.86‒
5.19]; I2=N/A) 
145/1000 more with long-term mortality when 
lower compared with higher initial oxygen 
concentration was used (18/1000 fewer to 
547/1000 more) 
NDI (moderate-
severe at 1‒3 years) 
Thamrin 2018181 69 Very low 1.08 ([95% CI, 0.58‒
2.03]; I2=N/A) 
28/1000 more with long-term NDI when lower 
compared with higher initial oxygen 
concentration was used (147/1000 fewer to 
360/1000 more)  
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Retinopathy of 
prematurity (Grade 
III‒V) 
Wang 2008166 Vento 2009167 
Kapadia 2013170 Aguar 2013171 
Rook 2014172 Oei 2017173 
441 Very low 0.75 ([95% CI, 0.43‒
1.33]; I2=0%) 
30/1000 fewer with retinopathy of prematurity 
when lower compared with higher initial 
oxygen concentration was used (67/1000 
fewer to 39/1000 more) 
Necrotizing 
enterocolitis (Bells’s 
Grade II‒III) 
Wang 2008166 Vento 2009167 
Kapadia 2013170 Aguar 2013171 
Rook 2014172 Oei 2017173 
441 Very low 1.62 ([95% CI, 0.66‒
3.99]; I2=0%) 
20/1000 more with necrotizing enterocolitis 
when lower compared with higher initial 
oxygen concentration was used (11/1000 
fewer to 95/1000 more) 
Bronchopulmonary 
dysplasia (moderate 
to severe) 
Wang 2008166 Vento 2009167 
Rabi 2011168 Kapadia 2013170 
Aguar 2013171 Rook 2014172 
Oei 2017173 
467 Very low 0.90 ([95% CI, 0.64‒
1.28]; I2=31%) 
37/1000 fewer with bronchopulmonary 
dysplasia when lower compared with higher 
initial oxygen concentration was used 
(132/1000 fewer to 102/1000 more) 
Major 
intraventricular 
hemorrhage (Grade 
III‒IV) 
Wang 2009166 Vento 2009167 
Kapadia 2013170 Aguar 2013171 
Rook 2014172 Oei 2017173 
441 Very low 0.84 ([95% CI, 0.50‒
1.40]; I2=12%) 
23/1000 fewer with major intraventricular 
hemorrhage (Grade III‒IV) when lower 
compared with higher initial oxygen 
concentration was used (73/1000 fewer to 
58/1000 more) 
CI indicates confidence interval; NDI, neurodevelopmental impairment; RCT, randomized controlled trial. 1 
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[h4]Subgroup Oxygen Concentration 21% Compared With 100% Oxygen Concentration 1 
(<35 Weeks’ Gestation) 2 
For the critical outcome of all-cause short-term mortality (in-hospital or 30 days), evidence 3 
of very-low certainty (downgraded for risk of bias and imprecision) from 4 RCTs with 484 4 
newborn infants at less than 35 weeks’ gestation receiving respiratory support at birth showed no 5 
statistically significant benefit or harm of initial room air (21% O2) compared with initial 100% 6 
oxygen concentration (RR, 1.58; 95% CI, 0.70‒3.55; I2=4%); 26/1000 more with short-term 7 
mortality when lower initial oxygen concentration (21%) compared with higher initial oxygen 8 
concentration (100%) was used (95% CI, 14/1000 fewer to 115/1000 more).166,168,170,173 9 
 For the critical outcome of all-cause long-term mortality (1‒3 years), in newborns at less 10 
than 35 weeks’ gestation, the results are the same as for all groups at less than 35 weeks’ 11 
gestation. 12 
 For the critical outcome of long-term NDI (moderate-severe, 1‒3 years) in preterm 13 
newborns (<35 weeks’ gestation), the results are the same as for all groups at less than 35 14 
weeks’ gestation. 15 
Additional subgroup analyses that evaluated the effect of varying the definition of low and high 16 
oxygen concentration (21%‒30% compared with 80%‒100% only; 30% compared with 90%‒17 
100%; 50% compared with 100%; 30% compared with 60%‒65%) and whether or not SpO2 18 
targeting as a co-intervention had any impact, found no differences in primary and secondary 19 
outcomes.9 When data from 2 observational cohort studies with 1225 newborns177,178 were 20 
pooled, initiating resuscitation with lower oxygen was associated with a statistically significant 21 
benefit in long-term mortality for all preterm newborns and the subgroup of 28 weeks’ gestation 22 
or less (RR, 0.77; 95% CI, 0.59‒0.99; I2=6%).9 23 
Soar 130 
© 2019 American Heart Association, Inc. 
[h3]Treatment Recommendations 1 
For preterm newborn infants (<35 weeks’ gestation) who receive respiratory support at birth, we 2 
suggest starting with a lower oxygen concentration (21%‒30%), rather than higher initial oxygen 3 
concentration (60%‒100%) (weak recommendation, very-low certainty of evidence). We suggest 4 
the range of 21% to 30% oxygen because all trials but 1 used this for the low oxygen 5 
concentration group. Subsequent titration of oxygen concentration using pulse oximetry is 6 
advised (weak recommendation, very-low certainty of evidence).  7 
Until further evidence is available, implementation of the suggested initial oxygen concentration 8 
between 21% to 30% should be based on local practice considerations and should be reevaluated 9 
with ongoing audit of care. 10 
[h3]Justification and Evidence to Decision Framework Highlights 11 
Balancing the benefits and serious potential harm of low versus high oxygen concentrations in 12 
neonatal care is a continuing concern, particularly for preterm infants. Decades of research 13 
clearly demonstrate that oxygen exposure is a determinant of critical neonatal outcomes in 14 
preterm infants. Concern remains that if the preterm infant requires resuscitation immediately 15 
after birth, the initial oxygen concentration to which the infant is exposed may be a critical 16 
contributor to outcomes, regardless of subsequent oxygen exposure. Both parents and clinicians 17 
rate the outcomes assessed in this SR as either critical or important. For all of the critical 18 
outcomes assessed in the meta-analyses of RCTs, the 95% CIs of RRs were wide enough to 19 
include both potential harm as well as potential benefit. Thus, it is unclear whether initial low or 20 
high oxygen concentrations may have undesirable effects. In suggesting starting with low 21 
oxygen concentrations (21%‒30%), we place value on avoiding exposure of preterm babies to 22 
additional oxygen without proven benefit for critical or important outcomes because we are 23 
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cognizant of harms in newborn animals and increased neonatal mortality in term infants exposed 1 
to high initial oxygen concentration.145,182 This review addressed only the initial concentration of 2 
oxygen and therefore does not include any recommendation for subsequent administration or 3 
titration of oxygen. Subsequent titration of supplementary oxygen should be based on published 4 
SpO2 target ranges. 5 
The a priori comparisons evaluated only an initial oxygen concentration of 21% to 30% versus 6 
80% to100%, which therefore influences the recommendation. We recognize that no studies have 7 
compared the safety or efficacy of commencing resuscitation with 21% versus intermediate 8 
concentrations such as 30% oxygen. We emphasize that the included studies measured only the 9 
effect of varying initial inspired oxygen concentrations and were not designed to assess the 10 
safety or efficacy of different SpO2 targets. As outlined above, careful attention should be paid to 11 
the initial as well as the cumulative oxygen load under the investigated regimes. Therefore, 12 
starting at a lower oxygen concentration (21%‒30%) with the option to titrate according to SpO2 13 
aiming for published SpO2 target ranges provides an option of minimizing oxygen exposure at 14 
birth.   15 
[h3]Knowledge Gaps 16 
The NLS Task Force identified the following knowledge gaps requiring further investigation, 17 
including 18 
 High-quality studies with appropriate power to determine optimal initial oxygen, as the 19 
95% CI for the primary outcome in most studies identified in this review includes both 20 
harm and benefit 21 
 Further evidence from randomized studies about long-term NDI outcomes 22 
 Studies to address the actual oxygen requirements for specific gestational age groups 23 
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 Further evidence to identify the optimal SpO2 targets for preterm infants 1 
 Evidence to identify optimal methods of titrating oxygen for preterm infants in the 2 
delivery room 3 
 Potential effects of delayed cord clamping on the impact of initial inspired oxygen 4 
concentration for preterm infant 5 
[h1]Education, Implementation and Teams (EIT) and Advanced Life Support (ALS) Task 6 
Forces 7 
[h2]Cardiac Arrest Centers Versus Non-Cardiac Arrest Centers  8 
Cardiac Arrest Centers (CACs) are hospitals providing evidence-based resuscitation treatments 9 
including emergency interventional cardiology, bundled critical care with TTM, and protocolized 10 
cardiorespiratory support and prognostication.48,62  11 
This PICOST was prioritized for review by the EIT and ALS Task Forces based on the 12 
publication of several large registry studies183,184 since the 2015 ILCOR CoSTR.185,186 In the 13 
following sections, we present a summary of the evidence identified by the ILCOR SR10 and the 14 
web-posted CoSTR about the effects of CACs.187 There was one question posted during the 15 
comment period regarding the definition of CACs and we’ve provided that in our introduction, 16 
above. 17 
[H3]Population, Intervention, Comparator, Outcome, Study Design, and Time Frame 18 
Population: Adults with attempted resuscitation after nontraumatic IHCA or OHCA 19 
Intervention: Specialized CAC care 20 
Comparators: Care at non-CAC 21 
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Outcomes:  1 
 Primary outcome: survival at 30 days or hospital discharge with favorable neurological 2 
outcome (Cerebral Performance Category 1 or 2 or modified Rankin Scale 0‒3)  3 
 Secondary outcomes: ROSC after hospital admission for patients with ongoing CPR, 4 
survival at 30 days and/or hospital discharge 5 
Study Designs: Published RCTs and nonrandomized studies (non-RCTs, interrupted time series, 6 
controlled before-and-after studies, cohort studies) reporting data from adult patients 7 
Time Frame: All years and all languages included (provided there was an English abstract);  8 
literature search updated on August 1, 2018 9 
PROSPERO registration: CRD42018091427 10 
[H3]Consensus on Science 11 
A total of 21 observational studies183,184,188-206 and 1 pilot randomized trial207 were included in 12 
the SR.10 Of these, 17 observational studies were ultimately included in meta-analysis.183,184,188-13 
194,199-206 All studies were in OHCA cohorts; 1 study195 also included patients with IHCA, but 14 
outcomes were not reported separately. 15 
The observational studies provided very-low certainty of evidence for all outcomes. The 16 
included studies all reported outcomes from patients with OHCA who were cared for at a CAC 17 
compared with those cared for at a non-CAC. The manner of arrival at a CAC or non-CAC 18 
varied greatly across studies (ie, prehospital triage of all patients to the closest hospital, 19 
prehospital triage of select patients to a CAC, prehospital triage of all patients to a CAC, 20 
secondary interhospital transfer from a non-CAC to a CAC, or not described). Given the 21 
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potential for referral bias and other confounding variables, only data from studies reporting 1 
adjusted measures of association were pooled in the meta-analysis.  2 
CACs were associated with favorable neurological outcome and survival when examined at 3 
hospital discharge, but this was nonsignificant when examined at 30 days (Table 16). 4 
In addition to the pooled data, 3 observational studies looking exclusively at long-term outcomes 5 
of patients discharged alive from hospitals reported that care at a CAC was associated with better 6 
patient survival.194,195,197 7 
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Table 16. Summary of Evidence Regarding Outcomes Associated With Care in Cardiac Arrest Centers 1 
Outcomes (Importance) 
 Studies, 
n=number of 
participants 
Certainty of 
the Evidence 
(GRADE) 
Odds Ratio (95% CI) 
Anticipated Absolute Effects, n 
Care at Other 
Hospital 
Risk Difference for Care at Cardiac 
Arrest Center 
Survival to 30 days with 
favorable neurological 
outcome (critical) 
2 studies183,184 
n=45,956 
Very low 2.92 
(95% CI, 0.6812.48) 
359/25,617 
(1.4%) 
26 more per 1000 
(from 4 fewer to 137 more) 
Survival to hospital 
discharge with favorable 
neurologic outcome 
(critical) 
2 studies189,190 
n=3673 
Very low 2.22 
(95% CI, 1.74‒2.84) 
47/584 
(8.0%) 
82 more per 1000 
(from 52 more to 119 more) 
Survival to 30 days (critical) 2 studies193,205 
n=2693 
Very low 2.14 
(95% CI, 0.73‒6.29) 
123/1695 (7.3%) 71 more per 1000 
(from 19 fewer to 257 more) 
Survival to hospital 
discharge (critical) 
5 studies189,190,200-
202 
 
n=11662 
Very low 1.85 
(95% CI, 1.46‒2.34) 
587/4117 (14.3%) 93 more per 1000 
(from 53 more to 138 more) 
CI indicates confidence interval; GRADE, Grading of Recommendations, Assessment, Development, and Evaluation. 2 
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Preplanned subgroup analyses identified additional information about the effects of primary 1 
transport versus secondary transfer of patients to CACs and about outcomes of patients with 2 
shockable versus nonshockable rhythms. Four observational studies examined the potential 3 
impact of transfer on patient outcomes from OHCA.184,194,204,206 One study206 reported higher 4 
adjusted patient survival associated with direct transfer to a CAC compared with patient survival 5 
among those who underwent secondary interfacility transfer (odds ratio [OR] 1.97; 95% CI, 6 
1.13‒3.43). Two other studies184,194 reported no difference in survival between direct transport 7 
versus secondary transfer of patients to a CAC. One study204 reported higher adjusted survival in 8 
patients who underwent a secondary transfer to a CAC compared with survival among those who 9 
remained at the initial treating non-CACs (OR, 1.59; 95% CI, 1.30‒1.93). One additional 10 
observational study189 reported higher adjusted patient survival to hospital discharge associated 11 
with bypassing the nearest non-CAC and transporting patients directly to a CAC, compared with 12 
transporting patients to non-CACs (OR, 3.02; 95% CI, 2.01‒4.53).  13 
Eight observational studies reported outcomes stratified by arresting rhythm into shockable or 14 
nonshockable cohorts, but the findings were inconsistent, most reported unadjusted data, and the 15 
studies were too heterogenous to pool.184,188,190,194,198,200,201,203  16 
[h3]Treatment Recommendations From the EIT and ALS Task Forces 17 
We suggest that adult patients with nontraumatic OHCA be cared for in CACs rather than in 18 
non-CACs (weak recommendation, very low certainty of evidence). 19 
We cannot make a recommendation for or against regional triage by primary EMS transport of 20 
patients with OHCA to a CAC (bypass protocols) or secondary interfacility transfer to a CAC. 21 
The current evidence is inconclusive, and confidence in the effect estimates is currently too low 22 
to support an EIT and ALS Task Force recommendation. 23 
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For patients with IHCA, we found no evidence to support an EIT and ALS Task Force 1 
recommendation. 2 
For the subgroup of patients with shockable or nonshockable initial cardiac rhythm, the current 3 
evidence is inconclusive, and the confidence in the effect estimates is currently too low to 4 
support an EIT and ALS Task Force recommendation. 5 
[h3]Justification and Evidence to Decision Framework Highlights 6 
In making this recommendation, the EIT and ALS Task Forces concluded that the potential 7 
benefits in clinical outcomes outweighed the potential risks and logistical issues with 8 
implementation.  9 
We specifically considered the consistency of improved outcomes in patients treated at CACs 10 
across most studies, the desirability of patients receiving evidence-based postresuscitation care, 11 
the evidence supporting specialized acute care for other emergency conditions (eg, trauma, 12 
stroke, and ST-segment elevation myocardial infarction), the lack of evidence suggesting clinical 13 
harm associated with longer transport times,208 the potential for referral bias (ie, transporting 14 
patients most likely to survive), and the implementation challenges of this recommendation.  15 
Regionalized systems of care for cardiac arrest may not be feasible in all areas, as the result of 16 
resource constraints, cost, and inherent regional differences in healthcare delivery. In making a 17 
weak recommendation in support of CACs, the task forces acknowledge the lack of high-level 18 
evidence.  19 
[h3]EIT and ALS Task Force Knowledge Gaps 20 
Numerous knowledge gaps were identified in this SR. Key gaps include the following: 21 
 There is no universal definition of a CAC. 22 
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 The precise aspects of CACs that improve outcomes have not been identified (eg, are 1 
there specific bundles of care that CACs offer that improve outcomes?). 2 
 The effect of delayed secondary interfacility transfer to a CAC is unknown.  3 
 The potential benefit of CACs for IHCA and other subgroups (eg, cardiac etiology, 4 
shockable rhythm) has not been reported.  5 
[h1]First Aid Task Force 6 
[h2]Presyncope 7 
Presyncope, or near-syncope, is the prodrome of syncope, and is characterized by light 8 
headedness, nausea, diaphoresis and a feeling of impending loss of consciousness. A progression 9 
to syncope results in global cerebral hypoperfusion and transient loss of consciousness; loss of 10 
postural tone can result in physical injury in up to 30% of patients.209 This review evaluated 11 
nonpharmacologic first aid interventions that can be applied at the onset or immediately after 12 
onset of presyncope symptoms. ILCOR commissioned an SR,11 and the task force studied all 13 
evidence cited in the SR and developed a draft CoSTR. The draft CoSTR was posted for public 14 
comment on the ILCOR website; the draft was viewed 285 times during the comment  period 15 
and no comments were posted.210 This document summarizes the final CoSTR for first aid 16 
treatment of presyncope. 17 
[h3]Population, Intervention, Comparator, Outcome, Study Design, and Time Frame 18 
Population: Adults and children with signs and symptoms of faintness or presyncope of 19 
suspected vasovagal or orthostatic origin  20 
Intervention: Physical counter-pressure maneuvers (PCMs), body positioning, hydration, or other  21 
Comparison: Compared with no intervention, or 1 intervention compared with another  22 
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Outcomes:  1 
 Abortion of syncope (termination of progression from presyncope to syncope) (critical) 2 
 Injuries or adverse events (critical)  3 
 Symptom improvement (important)  4 
 Change in heart rate (important)   5 
 Change in systolic blood pressure (important)  6 
 Change in diastolic blood pressure (important) 7 
Study Designs: RCTs and nonrandomized studies (non-RCTs, interrupted time series, controlled 8 
before-and-after studies, cohort studies) eligible for inclusion; case series and unpublished 9 
studies, published abstracts (eg, conference abstracts) and trial protocols excluded  10 
Time Frame: All years and all languages included (provided an English abstract was available)  11 
PROSPERO registration: CRD42018107726  12 
[h3]Consensus on Science 13 
[h4]Studies Comparing Use of PCMs With a Control or No Use of PCMs  14 
Eight studies were included in the SR, all evaluating use of PCM compared with no use of PCM. 15 
Physical counterpressure maneuvers involved the contraction of the large muscles of the legs, 16 
arms or abdomen, and included leg or arm tensing, crossing or squeezing, squatting, hand-grip, 17 
and abdominal compression. Studies included 2 RCTs 211,212 and 6 observational studies,211,213-217 18 
enrolling a total of 246 participants between 15 and 75 years of age with a history of vasovagal 19 
or orthostatic-related syncope. Forms of PCM evaluated included handgrip, squatting, leg 20 
crossing with tensing, and abdominal/core muscle tensing. Evidence from the Brignole RCT211 21 
was downgraded to very-low certainty as the result of risk of bias, inconsistency, indirectness, 22 
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and imprecision, whereas evidence from the Alizadeh RCT212 was downgraded to low certainty 1 
as the result of risk of bias, inconsistency, and indirectness. The observational studies all provide 2 
very-low-certainty evidence.211,213-217 See Table 17 for Summary of Studies.3 
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Table 17. 
Summary 
Data From 
Presyncope 
StudiesOutc
omes 
Intervention: Comparison 
Participants 
(Number of Studies) 
Relative Risk  
(95% CI) 
Certainty of 
Evidence 
(GRADE) 
Risk With 
Control/ 
no PCM 
Risk With 
Intervention 
(RD) 
Prevention  
of  
syncope 
Any PCM versus control  
(no use of PCM or standing 
only) 
92 OH and VVS 
etiology  
(4 observational)213-216 
1.31 (0.98‒ 
1.75)  
Very low 594 per 1000 184 more per 1000 
(from 12 fewer to 445 
more)  
RD=0.19 (0.01‒0.37) 
64 VVS etiology  
(3 observational)213-215 
2.20 (0.96‒
5.05)  
Very low 277 per 1000 222 more per 1000 
(from 11 fewer to 1000 
more) 
Lower-body PCM versus 
control  
(no use of PCM or standing 
only)  
36 VVS etiology  
(1 observational)215 
2.20 (0.96‒
5.05)  
Very low  333 more per 1000 
(from 3 more to 586 
more) 
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Table 17. 
Summary 
Data From 
Presyncope 
StudiesOutc
omes 
Intervention: Comparison 
Participants 
(Number of Studies) 
Relative Risk  
(95% CI) 
Certainty of 
Evidence 
(GRADE) 
Risk With 
Control/ 
no PCM 
Risk With 
Intervention 
(RD) 
Upper-body PCM versus  
control  
(no use of PCM or standing 
only) 
19 VVS etiology  
(1 RCT)211 
1.80 (1.16‒
2.79)  
Very low 526 per 1000 421 more per 1000 
(from 84 more to 942 
more) 
14 VVS etiology  
(1 observational)213 
29.00 (1.90‒
443.25)  
Very low   
37 VVS etiology 
2 observational)211,217 
99.4% of  
episodes  
(349/351)  
(RR not 
estimable,  
no 
comparisons) 
Very low   
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Table 17. 
Summary 
Data From 
Presyncope 
StudiesOutc
omes 
Intervention: Comparison 
Participants 
(Number of Studies) 
Relative Risk  
(95% CI) 
Certainty of 
Evidence 
(GRADE) 
Risk With 
Control/ 
no PCM 
Risk With 
Intervention 
(RD) 
Lower-body PCM versus  
upper-body PCM 
27 VVS etiology  
(1 observational)216 
7.00 (1.10‒
44.61) 
Very low  1000 more per 1000 
(from 88 more to 1000 
more)  
Injuries or  
adverse  
events 
Upper-body PCM versus  
control  
(no use of PCM or standing 
only) 
37 VVS etiology  
(2 observational)211,217 
0/37 (0%) 
(RR  
not estimable,  
no 
comparisons) 
Very low  0 fewer per 1000 
(0 fewer to 0 fewer) 
Symptom  
improveme
nt 
Any PCM versus control  
(no use of PCM or standing 
only) 
21 VVS etiology  
(1 observational)214 
20/20 (RR 
not  
estimable)  
Very low   
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Table 17. 
Summary 
Data From 
Presyncope 
StudiesOutc
omes 
Intervention: Comparison 
Participants 
(Number of Studies) 
Relative Risk  
(95% CI) 
Certainty of 
Evidence 
(GRADE) 
Risk With 
Control/ 
no PCM 
Risk With 
Intervention 
(RD) 
(one patient 
lost  
to follow-up) 
96 VVS etiology  
(1 RCT)212 
1.57 (0.98‒
2.51)  
 
Very low 440 per 1000 251 more per 1000 
(from 26 more to 409 
more)  
 
Lower-body PCM versus 
control  
(no use of PCM or standing 
only) 
96 VVS etiology  
(1 RCT)212 
1.66 (1.02‒
2.69)  
Very low  290 more per 1000 
(from 9 more to 744 
more) 
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Table 17. 
Summary 
Data From 
Presyncope 
StudiesOutc
omes 
Intervention: Comparison 
Participants 
(Number of Studies) 
Relative Risk  
(95% CI) 
Certainty of 
Evidence 
(GRADE) 
Risk With 
Control/ 
no PCM 
Risk With 
Intervention 
(RD) 
Upper-body PCM versus  
control  
(no use of PCM or standing 
only) 
19 VVS etiology  
(1 RCT)211 
6.00 (1.55‒
23.26)  
Low  526 more per 1000 
(from 58 more to 1000 
more) 
96 VVS etiology, 
follow-up phase 
(1 RCT)212 
1.47 (0.89‒
2.44)  
Very low  207 more per 1000 
(from 48 fewer to 634 
more 
Lower-body PCM versus  
upper-body PCM 
96 VVS etiology  
(1 RCT)212 
0.89 (0.65‒
1.22)  
Very low  80 fewer per 1000 
(from 30 fewer to 130 
more) 
Heart rate Upper-body versus control  
(no use of PCM or standing 
only) 
19 VVS etiology  
(1 RCT)211 
 Very low  MD: 8 per min higher  
(6.4 to 22.4 higher) 
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Table 17. 
Summary 
Data From 
Presyncope 
StudiesOutc
omes 
Intervention: Comparison 
Participants 
(Number of Studies) 
Relative Risk  
(95% CI) 
Certainty of 
Evidence 
(GRADE) 
Risk With 
Control/ 
no PCM 
Risk With 
Intervention 
(RD) 
Lower-body PCM versus  
upper-body PCM 
 
27 VVS etiology, 
handgrip versus  
squatting 
(1 observational)216 
  Very low  MD: 0.8 per  
min lower  
(5.5 lower to 3.9 higher) 
27 VVS etiology, leg-
crossing versus  
handgrip 
(1 observational) 216 
  Very low  MD 6.3 beats per minute 
higher  
(3.0‒9.5 beats per minute 
higher) 
Systolic  
blood  
pressure 
Any PCM versus control  
(no use of PCM or standing 
only) 
39 VVS etiology  
(2 observational)214,215 
  Very low  MD 21 mm Hg higher  
(18.25‒23.41) 
Lower-body PCM versus  18 VVS etiology   Very low  MD 19 mm Hg  
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Table 17. 
Summary 
Data From 
Presyncope 
StudiesOutc
omes 
Intervention: Comparison 
Participants 
(Number of Studies) 
Relative Risk  
(95% CI) 
Certainty of 
Evidence 
(GRADE) 
Risk With 
Control/ 
no PCM 
Risk With 
Intervention 
(RD) 
control  
(no use of PCM or standing 
only) 
(1 observational)215 higher 
 (16.31‒21.69) 
Upper-body PCM versus  
control  
(no use of PCM or standing 
only) 
19 VVS etiology  
(1 RCT)211 
  Low  MD 32 mm Hg higher 
 (12.48‒51.52)  
Lower-body PCM versus  
upper-body PCM 
27 VVS etiology, 
squatting versus  
handgrip 
(1 observational)216  
 
 Very low  MD 12.5 mm Hg higher  
(5.69‒19.31)  
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Table 17. 
Summary 
Data From 
Presyncope 
StudiesOutc
omes 
Intervention: Comparison 
Participants 
(Number of Studies) 
Relative Risk  
(95% CI) 
Certainty of 
Evidence 
(GRADE) 
Risk With 
Control/ 
no PCM 
Risk With 
Intervention 
(RD) 
27 VVS etiology, leg 
crossing  
versus handgrip 
(1 observational)216 
 Very low  MD 11.6 mm Hg higher  
(4.3‒18.8) 
Lower-body PCM versus  
abdominal PCM 
9 neurogenic OH 
etiology  
(1 observational)218 
 Very low  MD 36.5 higher 
(15.00‒57.99)  
Lower-body PCM versus 
neck PCM 
9 neurogenic OH 
etiology  
(1 observational)218 
 Very low  MD 28.2 higher  
(10.79‒45.61)  
Diastolic  
blood  
Any PCM versus control  39 VVS etiology  
(2 observational)214,215 
 Very low  MD 11 mm Hg higher  
(9.39‒13.10) 
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Table 17. 
Summary 
Data From 
Presyncope 
StudiesOutc
omes 
Intervention: Comparison 
Participants 
(Number of Studies) 
Relative Risk  
(95% CI) 
Certainty of 
Evidence 
(GRADE) 
Risk With 
Control/ 
no PCM 
Risk With 
Intervention 
(RD) 
pressure (co use of PCM or standing 
only) 
Lower-body PCM versus  
control  
(no use of PCM or standing 
only) 
18 VVS etiology  
(1 observational)215 
 Very low  MD 10 mm Hg higher  
(8.04‒11.96)  
Upper-body PCM versus 
control  
(no use of PCM or standing 
only) 
19 VVS etiology  
(1 RCT)211 
 Very low  MD 20 mm Hg higher  
(5.95‒34.05)  
Lower-body PCM versus  
upper-body PCM 
27 VVS etiology  
(1 observational) 216 
 Very low  MD 3.3 mm Hg higher  
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Table 17. 
Summary 
Data From 
Presyncope 
StudiesOutc
omes 
Intervention: Comparison 
Participants 
(Number of Studies) 
Relative Risk  
(95% CI) 
Certainty of 
Evidence 
(GRADE) 
Risk With 
Control/ 
no PCM 
Risk With 
Intervention 
(RD) 
(2.28 mm Hg lower to 
8.88)  
27 VVS etiology  
(1 observational) 216 
 Very low  MD 1.3 mm Hg higher  
(6.88 mm Hg lower  
to 4.28 mm Hg higher) 
CI indicates confidence interval; GRADE, Grading of Recommendations, Assessment, Development, and Evaluation; MD, mean 1 
difference; mm Hg, millimeters of mercury; OH, orthostatic hypotension; PCM, physical counterpressure maneuvers; RCT, 2 
randomized controlled trial; RD, risk difference; RR, relative risk; VVS, vasovagal syncope.3 
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[h5]Termination of Syncope. 1 
Use of handgrip PCM in 19 participants with vasovagal syncope and a positive tilt-table test 2 
increased likelihood of terminating syncope in 1 RCT.211 However, no association was found 3 
between the termination of syncope and any form of PCM in 4 observational studies in 4 
laboratory settings with tilt-table testing.213-216 In 2 observational follow-up studies of 37 5 
participants in settings of daily life,211,217 use of handgrip and arm tensing PCM was associated 6 
with termination of syncope in 99% of episodes involving subjects with known vasovagal origin 7 
presyncope. No adverse events or complications related to the use of handgrip PCM were 8 
reported in any of these studies.  9 
[h5]Alleviation of Symptoms of Presyncope. 10 
One RCT with 96 participants evaluated in daily life settings reported that the use of lower-body 11 
PCM (squatting) or upper-body PCM (handgrip) resulted in more alleviation of symptoms of 12 
presyncope than no PCM.212 A second smaller RCT211 in a tilt-table test setting found more 13 
symptom improvement with the use of handgrip PCM compared with no PCM. One 14 
observational follow-up study214 found symptom improvement in all 21 participants with 15 
vasovagal origin syncope in association with the use of lower-body PCM (squatting and 16 
abdominal tension). 17 
[h5]Increase in Heart Rate and Blood Pressure. 18 
An increase in heart rate after the use of handgrip PCM was reported in a single RCT,211although 19 
4 observational studies213-216 did not report consistent changes in heart rate. The same single 20 
RCT211 found improved systolic blood pressure with the use of handgrip PCM, and 2 pooled 21 
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observational studies214,215 reported increased systolic and diastolic blood pressure associated 1 
with the use of lower-body PCM. 2 
[h5]Subgroup Analysis. 3 
A subgroup weighted meta-analysis of 64 adults with vasovagal presyncope only, from 3 4 
observational studies, 214-216 failed to find an association between the use of PCM and reduced 5 
likelihood of progression from presyncope to syncope but did show an association with greater 6 
likelihood of symptom improvement and an increase in heart rate and blood pressure. 7 
[h5]Upper-Body Compared With Lower-Body PCM. 8 
The use of upper-body PCM compared with lower-body PCM was evaluated by 1 observational 9 
study216 which reported a greater likelihood for termination of syncope and increase in heart rate 10 
and blood pressure associated with the use of lower-body PCM. Results from 1 RCT212 did not 11 
find greater improvement in symptoms of presyncope with the use of lower-body PCM 12 
compared with upper-body PCM. 13 
[H5]Additional Interventions for Presyncope. 14 
No studies were identified evaluating the use of other interventions such as hydration or change 15 
of position applied at the onset of symptoms of presyncope. 16 
[h3]Treatment Recommendations 17 
We recommend the use of any type of PCM by individuals with acute symptoms of presyncope 18 
from vasovagal or orthostatic causes in the first aid setting (strong recommendation, low- and 19 
very-low-certainty evidence).  20 
We suggest that lower-body PCMs, such as leg crossing and tensing or squatting, are preferable 21 
to upper-body and abdominal PCMs (weak recommendation, very-low-certainty evidence). 22 
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[h3]Justification and Evidence to Decision Framework Highlights  1 
Despite the mixed results and low- or very-low-certainty evidence identified in this review, with 2 
use of the Evidence to Decision Framework210 and discussion of all evidence, the First Aid Task 3 
Force concluded that the use of PCM for acute symptoms of presyncope warranted a strong 4 
recommendation because, together, the included studies suggest that the use of PCM results in 5 
better outcomes with no reported adverse events. In addition, PCM interventions are simple and 6 
inexpensive, and they may prevent progression from presyncope to syncope and risks of 7 
subsequent injury. Successful treatment of presyncope may improve the quality of life for those 8 
with recurrent vasovagal or orthostatic syncope, and it may ultimately decrease associated 9 
healthcare costs. Included studies demonstrated that training of participants in use of PCM at 10 
symptom onset was feasible and similar to a first aid situation, making it likely that first aid 11 
providers can also be trained in their use. 12 
Although there is little evidence comparing different methods of PCM, observational studies 13 
suggested that the use of lower-body PCM may have an advantage over upper-body PCM for the 14 
outcome of terminating presyncope. Despite this, the task force recognizes the practicality in the 15 
use of a variety of PCM techniques for first aid, particularly when PCM interventions may be 16 
limited by patient location and position. 17 
[h3]Knowledge Gaps 18 
The task force identified several knowledge gaps requiring further investigation, including  19 
 Validity of conventional first aid recommendation to place a person with symptoms of 20 
presyncope into a sitting or supine position with or without combination of PCM  21 
 Effectiveness of additional interventions such as hydration 22 
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 Clinical outcomes related to the use of PCM and possible variation based on age, gender, 1 
and etiology of presyncope 2 
 Ability of first aid providers to recognize vasovagal and orthostatic presyncope and to 3 
assess clinical outcomes after instruction in and use of PCM 4 
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